* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Preview the material
Survey
Document related concepts
Remote ischemic conditioning wikipedia , lookup
Heart failure wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Cardiac surgery wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Myocardial infarction wikipedia , lookup
Jatene procedure wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Electrocardiography wikipedia , lookup
Ventricular fibrillation wikipedia , lookup
Atrial fibrillation wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Transcript
ARRHYTHMIAS IN CHILDREN: Diagnosis And Treatment Jassin M. Jouria, MD Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serves as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT The prevalence and spectrum of arrhythmias change with age. As a consequence, treating arrhythmias in children has its unique challenges. The child’s age, as well as the age of onset of arrhythmia, history of heart symptoms or failure, and electrocardiography testing must all be considered when making a diagnosis. Although not a common occurrence in children, life-threatening arrhythmias need to be identified and appropriately treated to prevent serious outcomes. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Continuing Nursing Education Course Planners William A. Cook, PhD, Director, Douglas Lawrence, MA, Webmaster, Susan DePasquale, MSN, FPMHNP-BC, Lead Nurse Planner Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities. Continuing Education Credit Designation This educational activity is credited for 4.5 hours. Nurses may only claim credit commensurate with the credit awarded for completion of this course activity. Pharmacology content is 1 hour. Statement of Learning Need There are unique challenges associated with arrhythmias in children and the treatment options for childhood arrhythmia. This information is needed to guide the healthcare professional who is treating children with arrhythmia. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 2 Course Purpose To provide nurses with knowledge of pediatric arrhythmias, including its recognition and treatment options. Target Audience Advanced Practice Registered Nurses and Registered Nurses (Interdisciplinary Health Team Members, including Vocational Nurses and Medical Assistants may obtain a Certificate of Completion) Course Author & Planning Team Conflict of Interest Disclosures Jassin M. Jouria, MD, William S. Cook, PhD, Douglas Lawrence, MA, Susan DePasquale, MSN, FPMHNP-BC – all have no disclosures Acknowledgement of Commercial Support There is no commercial support for this course. Activity Review Information Reviewed by Susan DePasquale, MSN, FPMHNP-BC Release Date: 8/10/2016 Termination Date: 8/10/2019 Please take time to complete a self-assessment of knowledge, on page 4, sample questions before reading the article. Opportunity to complete a self-assessment of knowledge learned will be provided at the end of the course. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 3 1. Any electrical activity not initiated by the SA node is considered a. b. c. d. a depolarization event. an atrioventricular (AV) impulse. an arrhythmia. a repolarization event. 2. Electrical stimulation of a myocardial cell results in a. b. c. d. a slow outward leak of sodium. depolarization. a slow outward leak of potassium. All of the above 3. True or False: Some arrhythmias are so common as to be considered as almost normal variants. a. True b. False 4. The conduction system in the ventricles is more elaborate than that in the atria because a. b. c. d. the muscle mass is larger. of the location of the bundle of His. the superior vena cava enters through the ventricles. of fiber stretch. 5. Normally, the _________________, located where the superior vena cava meets the right atrium, has the most rapid intrinsic rate (60 to 100 bpm). a. b. c. d. atria via atrioventricular (AV) node coronary sinus sinoatrial (SA) node nursece4less.com nursece4less.com nursece4less.com nursece4less.com 4 Introduction An arrhythmia is an abnormality of cardiac rhythm. The prevalence and spectrum of arrhythmias change with age. As a consequence, treating arrhythmias in children has its unique challenges. While abnormal heart rates in children are often not a cause of concern, children with an abnormal heart rhythm, including consideration of the child’s age, age of onset of arrhythmia, history (palpitations, heart failure, syncope, etc.), and the electrocardiogram (ECG) findings must all be factored into a health professional’s diagnosis. It is absolutely vital that a clinician be able to recognize when an arrhythmia has the potential to become serious or life threatening, and to identify appropriate treatment options. This course will provide an understanding of the mechanics of arrhythmias, and it will discuss the unique challenges associated with arrhythmias in children and the treatment options. This information will help healthcare professionals to communicate with their young patient and the patient’s parents or guardians to determine the right course of action. Cardiac Electrophysiology The majority of myocardial cells share the same basic cellular electrophysiologic properties that allow contraction when a transmembrane action potential develops. The electrical system of the heart consists of intrinsic pacemakers and conduction tissues. This section reviews normal cardiac rhythm in anatomic terms and highlights normal cardiac electrophysiology as a necessary basis for recognizing abnormal conditions as they may occur in children. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 5 Normal Cellular Electrophysiology Fully polarized cells have a resting membrane potential of -90 mV. This resting membrane potential exists because of the electrical gradient created by differences in extracellular and intracellular ion concentrations. Specifically, the sodium–potassium pump primarily controls sodium and potassium concentrations. This pump tries to maintain intracellular sodium concentrations at 5 to 15 mEq/L and intracellular potassium concentrations at 135 to 140 mEq/L. In comparison, the extracellular sodium concentration is normally 135 to 142 mEq/L and extracellular potassium 3 to 5 mEq/L.2 Electrical stimulation of a myocardial cell results in depolarization. Depolarization is initiated by a slow inward leak of sodium. When the transmembrane potential reaches approximately -60 mV, the fast sodium channel opens, actively transporting sodium across the cell membrane and resulting in rapid cellular depolarization to approximately +20 mV. This is represented by phase 0 of the action potential and the QRS complex on a surface electrocardiogram (ECG). After the rapid membrane depolarization, the sodium channel closes and a complex exchange of sodium, calcium, and potassium occurs during the plateau phases 1 and 2 of the action potential. The dominant feature during the plateau phases of the action potential is movement of calcium ions into the intracellular space via L-type calcium channels. This feature differentiates myocardial cells from nerve tissue and starts the excitation–contraction cascade of the cell by initiating the release of intracellular calcium stores from the sarcoplasmic reticulum. Phase 3 of the action potential is dominated by repolarization of the cell membrane by outward movement of nursece4less.com nursece4less.com nursece4less.com nursece4less.com 6 potassium ions. The rate of fall of phase 3 and its depth determine membrane responsiveness to stimulation. Tissues may depolarize only after reaching a particular level of repolarization called the ‘‘threshold potential,’’ at least -50 to -55 mV for normal Purkinje fibers. This level of repolarization therefore determines the absolute refractory period (ARP). The ARP varies in length depending primarily on the action potential duration (APD). Phase 4 is the resting membrane potential that results from a combination of ionic currents, primarily the slow inward sodium current.3 Normal Cardiac Conduction The electrical system of the heart consists of intrinsic pacemakers and conduction tissues. It is convenient to conceptualize the progression of normal cardiac rhythm in anatomic terms. The rate of electrical firing of the heart depends on the most rapid pacemaker. Spontaneous electrical firing or automaticity can occur anywhere in the heart under certain conditions. Normally, the sinoatrial (SA) node, located where the superior vena cava meets the right atrium, has the most rapid intrinsic rate (60 to 100 bpm). Therefore, any electrical activity not initiated by the SA node is considered an arrhythmia. Consequently, most arrhythmias are labeled by the anatomic location and rate. Sinoatrial node firing initiates atrial contraction. The electrical impulse is conducted through the atria via the internodal tracts to the atrioventricular (AV) node near the coronary sinus, between the two atria. The AV node has pacemaker properties but normally coordinates atrial and ventricular contraction. The AV node normally limits excessively rapid atrial rates from activating the ventricles. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 7 The conduction system in the ventricles is more elaborate than that in the atria because the muscle mass is larger. Rapid and effective excitation is critical because the ventricles contribute the most to cardiac output. Fibers leaving the AV node are called the bundle of His. They separate into the bundle branches, which traverse the septum between the ventricles. Conduction between the AV node and the bundle of His is measured by the P-R interval. The final conducting components of the ventricles are the Purkinje fibers, which emanate from the bundle branches to stimulate the ventricular cardiac muscle to contract. The QRS complex measures depolarization of the ventricles. The Q-T interval reflects both ventricular depolarization and repolarization. Electrical Anatomy of the Normal Heart The atrial muscle and ventricular muscle are separated by insulation of the fibrous mitral and tricuspid valve rings, and normally the only connection between them is via the His bundle. All cardiac myocytes are capable of electrical conduction and have intrinsic pacemaker activity. Each tissue has a conduction velocity and a refractory period, both of which vary with changes in heart rate and influences such as autonomic tone, circulating catecholamines, etc. The conduction velocities of various parts of the heart vary.8 Cardiac Conduction The cardiac conduction system consists of specialized fast conducting tissue through which the electric activity of the heart spreads from the atria to the ventricles. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 8 The characteristics of the different parts of the conduction system are a result of the different characteristics of the individual myocytes. On a larger level, function is controlled predominantly by the autonomic nervous system (both vagal and sympathetic nerve system). The sinus node and atrioventricular node are especially responsive to the autonomic nerve system. The ganglionic plexus, a conglomeration of both vagal and sympathetic nerves, form the intrinsic cardiac nerve system and innervate through a network of nerve fibers in the atria and ventricles. The vagal nerve and sympathetic nerve system are both continually active in the heart, but vagal activity dominates the tonic background stimulation of the autonomic nerve system. Moreover, the heart is more susceptible to vagal stimulation. Vagal stimulation provokes a rapid response and the effect dissipates swiftly in contrast to sympathetic stimulation, which has a slow onset and offset. Vagal stimulation results in a reduction in sinus node activation frequency and prolongs AV nodal conduction. These effects can occur simultaneously or independent of each other. Sympathetic stimulation exerts reverse effects, accelerating the sinus node firing frequency and improving AV nodal conduction. The autonomic nerve system has a small effect on cardiomyocytes. Vagal stimulation tends to prolong the refractory period and decrease the myocardial contractility. Sympathetic stimulation has the opposite effect on the cardiac tissue. The physiological modulation of cardiac conduction is vital to adaptation of the heart to rest and exercise. However, the autonomic nervous system can contribute as a modifier and is certain to facilitate the occurrence of certain arrhythmias.9 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 9 Sinus Node The sinus node is a densely innervated area located in the right atrium, which is supplied by the right (55%-60%) or circumflex (40%-45%) coronary artery. It is a small structure of 10-20 mm long and 2-3 mm wide and contains a diversity of cells. These include pacemaker cells, which are discharged synchronously due to mutual entrainment. This results in an activation wave front triggering the rest of the atrium. Atrium The impulse formed in the sinus node is conducted through the atrium to the AV-node. Evidence indicates three preferential conduction pathways. The pathways show preferential conduction due to their anatomical structure, rather than specialized conduction properties. The three pathways are: the anterior internodal pathway, the middle internodal tract, and the posterior internodal pathway. The anterior internodal pathway connects to the anterior interatrial band, also known as the Bachmann bundle. This bundle of muscular tissue conducts the sinus wave front from the right to the left atrium. AV Node The connection between atria and ventricles is facilitated through the AV node, lying in the right atrial myocardium and a penetrating part, the bundle of His. The AV node acts as a gatekeeper, regulating impulse conduction from the atrium to the ventricle. Additionally, due to the phase 4 diastolic depolarization it can exhibit impulse formation. The AV node is supplied in most cases (85%-90%) by the right coronary artery or in the remaining cases the circumflex artery. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 10 Bundle of His Connecting the distal AV node and the proximal bundle branches, the bundle of His is supplied by both the posterior and anterior descending coronary arteries. The central fibrous body and membranous septum between the atria and the ventricles enclose it. The location and blood supply protect the bundle of His from external influences. Bundle Branches From the bundle of His, the right bundle branch continues to the right ventricular apex. The left bundle branch splits off and divides into to two fascicular branches. Commonly, the left bundle branch consists of an anterior fascicle, which activates the anterosuperior portion of the left ventricle, and the thicker and more protected posterior fascicle, which activates the inferoposterior part of the left ventricle. Ventricle The ventricle is activated through the dense network of Purkinje fibers originating from the bundle branches. They penetrate the myocardium and are the starting point of the ventricular activation. The left ventricular areas first excited are the anterior and posterior paraseptal wall and the central left surface of the interventricular septum. The last part of the left ventricle to be activated is the posterobasal area. Septal activation starts in the middle third of the left side of the interventricular septum, and at the lower third at the junction of the septum and posterior wall. Activation of the right ventricle starts near the anterior papillary muscle 5 to 10 milliseconds after onset of the left ventricle.10 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 11 Normal Heart Rate In Children The normal average heart rate of children is higher than that of adults. A heart rate of 60 to 100 bpm when resting is considered normal for adults. The variation in heart rates of children is greater with heart rates varying from 60 bpm (when they are asleep) to 220 bpm (when they are active physically in strenuous activities).6 Age Normal Range (Average) bpm < 1 day 93-154 (123) 1-2 days 91-159 (123) 3-6 days 91-166 (129) 1-3 weeks 107-182 (148) 1-2 months 121-179 (149) 3-5 months 106-186 (141) 6-11 months 109-169 (134) 1-2 years 89-151 (119) 3-4 years 73-137 (108) 5-7 years 65-133 (100) 8-11 years 62-130 (91) 12-15 years 80-119 (85) > 16 years 60-100 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 12 Cardiac Arrhythmias An arrhythmia is any abnormality in the rate, regularity, or site of origin of an electrical impulse. Arrhythmia includes a disturbance in conduction that disrupts the normal sequence of activation in the atria or ventricles. Arrhythmias have varying degrees of severity and significance based on site of origin, symptoms, frequency, and duration; and, they can be due to a variety of reasons, such as structural abnormalities, electrolyte abnormalities, metabolic derangements, genetic mutations, and drug toxicity. This section provides an overview of cardiac arrhythmias in terms of pathogenesis and clinical presentation. Overview of Arrhythmias Arrhythmias are relatively common in the pediatric cardiac intensive care unit. One study revealed 59% of neonates and 79% of older children have arrhythmias within 24 hours of surgery. An arrhythmia is any abnormality in the rate, regularity, or site of origin or a disturbance in conduction that disrupts the normal sequence of activation in the atria or ventricles. Arrhythmias differ in their population frequency, anatomical substrate, physiological mechanism, etiology, natural history, prognostic significance, and response to treatment. As is emphasized throughout, it is important to gain as much information as possible about the substrate and mechanism of an arrhythmia to be able to predict the natural history and to define the prognosis and response to treatment.1 A basic knowledge of the cardiac action potential and cardiac conduction system facilitates understanding of cardiac arrhythmias. The effects and side effects of anti-arrhythmic drugs are nursece4less.com nursece4less.com nursece4less.com nursece4less.com 13 depended on the influence of ion channels involved in the generation and/or perpetuation of the cardiac action potential. These physiological dynamics are explained further below.3,7 The cardiac action potential is a result of ions flowing through different ion channels. Ion channels are passages for ions (mainly Na+, K+, Ca2+ and Cl-) that facilitate movement through the cell membrane. Changes in the structure of these channels can open, inactivate or close these channels and thereby control the flow of ions into and out of the myocytes. Due to differences in the type and structure of ion channels, the various parts of the heart have slightly different action potential characteristics. Ion channels are mostly a passive passageway where movement of ions is caused by the electrochemical gradient. In addition to these passive ion channels a few active trigger-dependent channels exist that open or close in response to certain stimuli (for instance acetylcholine or ATP). The changes in the membrane potential due to the movement of ions produce an action potential, which lasts only a few hundreds of milliseconds. Disorders in single channels can lead to arrhythmias, as seen in the later section on primary arrhythmias. The action potential is propagated throughout the myocardium by the depolarization of the immediate environment of the cells and through intracellular coupling with gap-junctions. During the depolarization, sodium ions (Na+) stream into the cytoplasm of the cell followed by an influx of calcium (Ca2+) ions (both from the inside (sarcoplasmatic reticulum) and outside of the cell). These Ca2+ ions cause the actual muscular contraction by nursece4less.com nursece4less.com nursece4less.com nursece4less.com 14 coupling with the muscle fibers. During repolarization the cell returns to the resting membrane potential, due to the passive efflux of K+. The (ventricular) action potential can be divided in five phases, which are listed below in detail. Phase 0: Rapid Depolarization Rapid depolarization is started once the membrane potential reaches a certain threshold (about -70 to -60 mV). This produces activation of sodium channels and a rapid influx of Na+ and a corresponding rapid upstroke of the action potential. At higher potentials (-40 to -30) Ca2+ influx participates in the upstroke. In the sinus node and AV node a slower upstroke can be observed. This is because the slower acting Ca2+ ion channels mainly mediate the rapid depolarization in these cells. The slower activation produces a slower upstroke. Phase 1: Early Rapid Repolarization Immediately following rapid depolarization, the inactivation of the Na+ channel (INa) and subsequent activation of the outward K+ channel (Ito) and the Na+/Ca2+ exchanger (INa,Ca), which exchanges 3 Na+ for 1 Ca2+, produces an early rapid repolarization. Due to the limited role of the Na+ channel in the upstroke of sinus node and AV node cells and the subsequent slower depolarization, this rapid repolarization is not visible in their action potentials. Phase 2: Plateau The plateau phase represents an equal influx and efflux of ions in or out of the cell producing a stable membrane potential. This plateau phase is predominantly observed in the ventricular action potential. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 15 The inward movement of Ca2+ through the open L-type Ca2+ channels (ICa-L) and the exchange of Na+ for internal Ca2+ by the Na+/Ca2+ exchanger (INa,Ca) are responsible for the influx of ions during the plateau phase. The efflux of ions is the result of outward current carried by K+ (IKur and Ks). Phase 3: Final Rapid Repolarization Final repolarization is mainly caused by inactivation of Ca2+ channels, reducing the influx of positive ions. Furthermore repolarizing K+ currents (delayed rectifier current IKs and IKr and inwardly rectifying current IK1 and IK,Ach) are activated which increase efflux of positive K+ ions. This results in a repolarization to the resting membrane potential. Phase 4: Resting membrane potential During phase 4 of the action potential intracellular and extracellular concentrations of ions are restored. Depending on cell type the resting membrane potential is between -50 to -95 mV. Sinus node and AV nodal cells have a higher resting membrane potential (-50 to -60 mV and -60 to -70 respectively) in comparison with atrial and ventricular cardiomyocytes (-80 to -90 mV). Sinus node cells and AV nodal cells (and to a lesser degree Purkinje fiber cells) have a special voltage dependent channel If, the funny current. Furthermore they lack IK1, a K+ ion channel that maintains the resting membrane potential in atrial and ventricular tissue. The If channel causes a slow depolarization in diastole, called the phase 4 diastolic depolarization, which results in normal automaticity. The frequency the sinus node discharges is regulated by the autonomous nerve system, and due to nursece4less.com nursece4less.com nursece4less.com nursece4less.com 16 the relative high firing frequency (60-80 beats per minute) the sinus node dominates other potential pacemaker sites. Arrhythmogenesis In general, arrhythmia mechanisms have been described as abnormalities in electrical development, electrical conduction, or a combination of both. Abnormalities in electrical development arise from irregular automaticity or triggered activity from the SA node or other sites producing ectopic beats. Causes of irregular automaticity include hypoxia, electrolyte abnormalities, fiber stretch, catecholamine excess, ischemia, and edema. All of these factors increase the slope of phase 4 depolarization, resulting in heightened automaticity. Triggered activity usually develops due to transient membrane depolarization during or immediately after repolarization. These early and delayed afterdepolarizations can occur with oscillations in the plateau phase of the action potential, leading to a second depolarization before the first is completed. Hypoxia, fiber stretch, catecholamines, high PCO2, and digitalis overdose can lead to triggered activity.4 Reentry and conduction block are the most common electrical conduction abnormalities associated with arrhythmogenesis. Reentry describes a concept of infinite impulse propagation by continued activation of previously refractory tissue. Reentry depends on different conduction velocities along adjacent myocardial fibers, with one fiber containing an area of unidirectional conduction block. This allows continued excitation in a repetitive manner. This circus rhythm may develop as areas of infarcted tissue block or delayed conduction. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 17 A single circuit of the fibers may induce a premature contraction, whereas continuous cycling of impulses might produce sustained tachycardia. This process may occur in both atrial and ventricular tissue. Conduction block occurs when the normal conduction pathway is blocked and the impulse either expires or conducts through an alternative inappropriate route to depolarize the myocardium.5 Mechanisms of Arrhythmia Structural abnormalities or electric changes in the cardiomyocytes can impede impulse formation or change cardiac propagation, therefore facilitating arrhythmias. Arrhythmogenic mechanisms can arise in single cells (automaticity, triggered activity), but other mechanisms require multiple cells for arrhythmia induction (reentry). Briefly highlighted is the pathophysiological mechanisms of the main causes of arrhythmia.2,11 Abnormal Automaticity The mechanism of abnormal automaticity is similar to the normal automaticity of sinus node cells. Abnormal automaticity can be caused by changes in the cell ion channel characteristics due to drugs (digoxin) or changes in the electrotonic environment (myocardial infarction). Abnormal automaticity can result from an increase of normal automaticity in non-sinus node cells or a truly abnormal automaticity in cells that don't exhibit a phase 4 diastolic depolarization. An important phenomenon in (both normal and abnormal) automaticity is overdrive suppression. In overdrive suppression the automaticity of cells is reduced after a period of high nursece4less.com nursece4less.com nursece4less.com nursece4less.com 18 frequency excitation. The cellular mechanism responsible for this effect is an increased activity of the Na+, K+ pump (INa, K) which results in an increased efflux of Na+, thereby inducing a hyperpolarization. Triggered Activity Triggered activity is depolarization of a cell triggered by a preceding activation. Due to early or delayed afterdepolarizations the membrane potential depolarizes and, when reaching a threshold potential, activates the cell. These afterdepolarizations are depolarizations of the membrane potential initiated by the preceding action potential. Depending on the phase of the action potential in which they arise, they are defined as early or late afterdepolarizations. A disturbance of the balance in influx and efflux of ions during the plateau phase (phase 2 or 3) of the action potential is responsible for the early afterdepolarizations. Multiple ion currents can be involved in the formation of early afterdepolarizations depending on the triggering mechanism. Early afterdepolarizations can develop in cells with an increased duration of the repolarization phase of the action potential, as the plateau phase is prolonged. The prolonged repolarization might reactivate the Ca2+ channels that have recovered from activation at the beginning of the repolarization. Otherwise disparity in action potential duration of surrounding myocytes can destabilize the plateau phase through adjacent depolarizing currents. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 19 Delayed afterdepolarizations occur after the cell has recovered after completion of repolarization. In delayed afterdepolarization an abnormal Ca2+ handling of the cell is responsible for the afterdepolarizations due to release of Ca2+ from the storage of Ca2+ in the sarcoplasmatic reticulum. The accumulation of Ca2+ increases membrane potential and depolarizes the cell until it reaches a certain threshold, thereby creating an action potential. A high heart rate can result in the accumulation of intracellular Ca2+ and induce delayed afterdepolarizations.11 Disorders of Impulse Conduction The disorders of impulse conduction generally involve the rate of and re-entry circuits or pathways in the heart. Conduction block Conduction block or conduction delay is a frequent cause of bradyarrhythmias, especially if the conduction block is located in the cardiac conduction system. However, tachyarrhythmias can also result from conduction block when this block produces a re-entrant circuit. Conduction block can develop in different (pathophysiological) conditions or can be iatrogenic (medication, surgery). Re-entry Re-entry or circus movement is a multicellular mechanism of arrhythmia. Important criteria for the development of re-entry are a circular pathway with an area in this circle of nursece4less.com nursece4less.com nursece4less.com nursece4less.com 20 unidirectional block and a trigger to induce the re-entry movement. Re-entry can arise when an impulse enters the circuit, follows the circular pathway and is conducted through a unidirectional (slow conducting) pathway. Whilst the signal is in this pathway the surrounding myocardium repolarizes. If the surrounding myocardium has recovered from the refractory state, the impulse that exits the area of unidirectional block can reactivate this recovered myocardium. This process can repeat itself and thus form the basis of a re-entry tachycardia. Slow conduction and/or a short refractory period facilitate re-entry. The reason of unidirectional block can be anatomical (atrial flutter, AV node reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT) or functional (as with myocardial ischemia), or a combination of both. Epidemiology of Arrhythmias Some arrhythmias are more common than others but there are almost no data on the population prevalence of these conditions. However, the prevalence and spectrum of arrhythmias change with age. Faced with a new patient with an arrhythmia, diagnosis is based mainly on the child’s age, the age of onset of arrhythmia, the history (palpitations, heart failure, syncope, etc.), and the ECG findings, but should also take into account the prevalence of different nursece4less.com nursece4less.com nursece4less.com nursece4less.com 21 arrhythmias (in other words, a common arrhythmia is often a more likely diagnosis than a rare one). Probably fewer than half of new tachycardias present in the first year of life. By far the most common tachycardia presenting in early infancy is orthodromic AV reentry. Most of these infants have a normal ECG in sinus rhythm but some show ventricular preexcitation. Other neonatal tachycardias are much less common and include atrial flutter, permanent junctional reciprocating tachycardia, atrial tachycardia, and ventricular tachycardia.12 The most common tachycardia in childhood is also orthodromic AV reentry tachycardia, although AV nodal re-entry tachycardia becomes progressively more common after the age of 5 years. Less common tachycardias in this age group are antidromic AV re-entry, atriofascicular re-entry, ventricular tachycardias, and atrial tachycardias.5 Arrhythmias presenting with palpitations include most of the common types of supraventricular tachycardia and a few cases of ventricular tachycardia. Many children with palpitations do not have an arrhythmia and a detailed first-hand history is essential before assessing the likelihood of an arrhythmia and the necessity of further investigation. Similarly, very few children with chest pain have arrhythmias (or indeed any cardiac abnormality) and only a few with syncope have an arrhythmia. Again it all depends on the history. Incessant tachycardias presenting with heart failure or apparent cardiomyopathy include focal atrial tachycardia, permanent junctional nursece4less.com nursece4less.com nursece4less.com nursece4less.com 22 reciprocating tachycardia, incessant idiopathic infant ventricular tachycardia, and orthodromic atrioventricular re-entry tachycardia.13 Arrhythmias presenting with syncope include complete AV block, atrial fibrillation in Wolff–Parkinson–White (WPW) syndrome, sinoatrial disease, and ventricular tachycardia, especially in long QT syndrome, catecholaminergic ventricular tachycardia or late after cardiac surgery. Some arrhythmias are so common as to be considered as almost normal variants. They include atrial premature beats, ventricular premature beats, and transient nocturnal Wenckebach AV block. Arrhythmias are relatively common in the pediatric cardiac intensive care unit. One study revealed 59% of neonates and 79% of older children have arrhythmias within 24 hrs. of surgery. Of these arrhythmias, junctional ectopic tachycardia (JET) was seen in 9% of neonates and 5% of older children. Ventricular tachycardia was found in 3% of neonates and 15% of older children.14 In terms of specific arrhythmias, sinus tachycardia is the most frequently seen arrhythmia, with supraventricular tachycardia being the next most common, followed by sinus bradycardia. Reentrant tachycardia is common in infants and children with congenital heart disease (CHD). Some arrhythmias nursece4less.com nursece4less.com nursece4less.com nursece4less.com 23 in the early post operative period like premature atrial contraction’s (PAC’s) and premature ventricular beats (bigeminy) are usually transient and well tolerated. Others like junctional ectopic tachycardia (JET) and atrial flutter may cause significant hemodynamic instability and compromise or even sudden cardiac death. Primary arrhythmias occur in children without structural heart disease, although they may be secondary to ion channel diseases that are still being elucidated. Risk factors that predispose children for secondary arrhythmias include congenital cardiac malformations, surgical repair and scarring, long cardiopulmonary bypass times, or exposure to chronic hemodynamic stress. Electrolyte and acid-base imbalance and the use of vasoactive drugs also predispose children to arrhythmias. Inflammation or carditis seen in diseases such as acquired heart diseases like Kawasaki disease, rheumatic fever and myocarditis may produce arrhythmogenic foci. Conditions of ventricular volume overloading, valvular regurgitation, congestive heart failure and pulmonary hypertension are other secondary reasons. Regardless of the cause of the arrhythmia, there are certain common signs, symptoms and treatment options that are ultimately based on the rhythm more than on the etiology with certain very important exceptions. Symptoms may vary depending upon age and include feeding intolerance, lethargy, irritability, pallor, diaphoresis, syncope, fatigue or palpitations.3,8 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 24 Mechanisms of tachyarrhythmias can be enhanced automaticity with triggered foci or enhanced conduction with the presence of reentrant circuits. Similarly, bradycardia can result from suppressed automaticity or suppressed conduction, where normal conduction is delayed or blocked. Understanding the mechanism informs the optimal treatment choice. Types of Arrhythmias The following tables provide a general overview of the different types of arrhythmias.2,7,15,16 Sections of this course later on will provide more detailed information on the most common types. CARDIAC ARRHYTHMIA Sick sinus syndrome (SSS)/ Tachy-Brady Syndrome CHARACTERISTICS Sinoatrial (SA) node becomes dysfunctional and is no longer a reliable pacemaker, most commonly manifested as bradycardia, although there can also be tachycardia. When the sinus rate is slower than another potential pacemaker in the heart, it may no longer be the dominant pacemaker. SSS can also cause an alternating bradycardia and tachycardia. A number of rhythms result including sinus bradycardia, sinus arrest and junctional rhythm, and ectopic atrial and nodal rhythms. The term SSS includes SA node dysfunction plus symptoms of dizziness, syncope or sudden cardiac death. Bradycardias Often caused by hypoxia, vagal tone, hypothyroidism, cardiac surgery, endocarditis and myocarditis, hyperkalemia, sleep, hypothermia, sedation and anesthesia. Sinus bradycardia: Sinus node slower than normal for age related normal values. Slow junctional escape rhythm/nodal rhythm: Spontaneous depolarization of the AV node. The sinus node has either failed to fire or is slower than the AV node. Rates 50-80 beats/min in children less than 3 yrs. and 40-60 beats/min for children older than 3yrs. Can be common after atrial surgery and are usually transient. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 25 Ventricular escape rhythm or ideoventricular rhythm: Origin of impulse is from the ventricle and presents with rates slower than from the AV node. QRS have wide complex morphology. This is a secondary phenomenon vs. a primary arrhythmia and occurs when the sinus node and/or the AV node are dysfunctional. An example of this is complete heart block with a ventricular escape rhythm. The ventricle itself is working well, and the escape rhythm is a symptom of another problem. Premature Beats/ExtraSystoles Premature atrial, junctional and ventricular ectopic beats are common and may occur in patterns of bigeminy, trigeminy, quadrageminy or couplets. These are generally benign. Wandering Atrial Pacemaker Shifting of the pacemaker site from the SA node to alternate sites in the atria and junction (AV node). P-wave configuration changes as the site changes. Supraventricular Tachycardias (SVT) SVT is used as a collective term Originates above the bundle of His. Reentrant circuits generally have an abrupt onset and termination, i.e., are paroxysmal. Sinus tachycardia: Sinus node is faster than age-related normal values due to enhanced automaticity. Usually due to fever, pain, anxiety, anemia, medications, hypovolemia or in the presence of increased catecholamines. While not generally an indication of conduction system pathology, sinus tachycardia may be an important indicator of significant cardiovascular compromise. Reentrant tachycardias: Reentrant tachyarrhythmias require the presence of two possible conduction pathways with different conduction and refractory properties. The tachycardia uses both pathways; one as an antegrade limb and one as a retrograde limb of the reentry circuit. a) Within the atria: atrial flutter, atrial fibrillation; intraatrial reentrant tachycardia (IART) atrial flutter- or incisional tachycardia represents macroreentry within the atrial muscle and may be slower than atrial flutter. b) Atrioventricular reentrant tachycardias include: - atrioventricular reentrant tachycardia (AVRT): commonly associated with Wolff- Parkinson-White. Accessory pathway present allowing impulses that entered via the AV node to enter the atria - atrioventricular nodal reentry tachycardia (AVNRT): uses a “slow-fast AV nodal pathway”. Antegrade conduction limb is the slow pathway and retrograde limb fast one. Simulation of the atria by the retrograde pathway produces inverted p- waves. Concurrent stimulation of the ventricles. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 26 - permanent junctional reciprocating tachyarrhythmia (PJRT). These are reentrant circuits in which one limb includes the AV node. Wolff-Parkinson-White Syndrome (WPW): Baseline resting ECG is characterized by a short PR interval, wide QRS and delta wave which is a manifestation of the accessory on sinus rhythm. WPW is marked by the delta wave on the resting ECG. Atrial flutter or atrial fibrillation in the presence of this type of accessory connection can result in VF. The QRS complex in SVT is wide if there’s aberrant conduction, in which the antegrade limb is the accessory connection. If the AV node is the antegrade limb, the QRS is a narrow complex. Automatic tachycardia – AET and JET: local enhanced automatic focus of certain cardiac myocytes in the atria or AV node. AET and JET are non-reciprocating tachycardias that originate from a single focus unlike reentrant rhythms. AET/JET are seen more commonly in neonates and usually observed within the first several days after cardiopulmonary bypass. They are refractory arrhythmias that are relatively resistant to treatment. The goal is rate control and restoring AV synchrony. These are often transient arrhythmias lasting 24-72 hours. Rapid rates lead to early contraction of the atria against closed AV valves resulting in cannon A waves on hemodynamic monitoring lines (CV, RA, and LA). AET - When this occurs at an ectopic site within the atria, it is called atrial ectopic tachycardia. AET occurs as a result of irritation of tissues during cardiac surgery, with placement of intracardiac lines, application of sutures, or cutting tissue. Any reason for dilated atria, cardiomyopathy or diseased AV valves, ventricular dysfunction can result in this rhythm disorder. Rates are usually above 170-180 beats/min and beyond 200 beats/min. A block at the AV node can cause AV dissociation, further contributing to hemodynamic instability in addition to the rapid atrial rate. The rhythm may be variable, and may be interspersed with periods of sinus rhythm. The rate can ramp up or slow down over minutes in contrast to the sudden onset and offset of SVT. JET - When the ectopic focus initiates at or near the AV node then the arrhythmia is junctional ectopic tachycardia. JET is usually caused by surgery around the AV node and rates often range between 160 beats/min to as high as 280 beats/min. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 27 Characteristics include inverted P- waves in lead II and an R-P interval, which is short or absent. Primarily seen post re-warming from cardiopulmonary bypass and within 3 days of the surgery. Ventricular tachycardia (VT) Three or more consecutive ventricular complexes are by definition VT. Wide QRS complex morphology and a different QRS morphology than the usual QRS waveform characterize VT. Morphology may be monomorphic (uniform), polymorphic (multiform); or Torsades de Pointes where the points seem to twist around the isoelectric line. Often associated with structural heart disease, particularly late (years) after repair. Other common clinical situations in which one might see VT include dilated and hypertrophic cardiomyopathy, metabolic alterations including severe hypoxia, acidosis, hyper/hypokalemia, and drug toxicity such as cocaine, digoxin, and tri-cyclic antidepressants. Other conditions include myocarditis and long Q-T syndrome. Whenever VT occurs in a pediatric patient one must also consider ischemia or infarction. Patients may present hemodynamically stable or in cardiac arrest. Ventricular Fibrillation (VF) Completely uncoordinated depolarization of heart muscle mass resulting in inability to maintain any global excitation contraction coupling. The myocardium fails to squeeze and cardiac arrest occurs. 1st Degree Heart Block Slowed conduction through the AV node resulting in prolonged duration of PR interval. 2nd Degree Heart Block (Mobitz I, Wenckebach) Intermittent block of conduction of atrial beats to the ventricle resulting in dropped QRS complexes. Progressive lengthening of the PR interval until a QRS is dropped and the cycle starts again with a shorter PR interval that progressively lengthens. 2nd Degree Heart Block (Mobitz II; Classical type) Patterned dropping of QRS complex with a fixed ratio of atrial depolarizations (P waves) to conducted beats with a consistent PR interval throughout. It is higher risk than Mobitz I. Intermittent block of conduction of some beats to the ventricle without progressive prolongation of the PR interval. Potentially may progress to complete heart block. Related to His bundle or bundle branch dysfunction. 3rd Degree Heart Block/ Complete Heart Block Complete block of AV node resulting in AV dissociation between atrial and ventricular events. No relationship between the P waves and QRS complexes. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 28 Specific Categories of Cardiac Arrhythmias As noted earlier, there are many reasons for arrhythmias. Increased end diastolic pressures resulting in atrial or ventricular stretch, valvular dysfunction, tumors, multiple surgeries, scarring and ischemia all play a significant role in arrhythmia generation. Cardiac swelling, pro-arrhythmic drugs, acid/base and electrolyte imbalance are also frequent etiologies of rhythm issues. Neonatal Arrhythmias Common arrhythmias in neonates with structurally normal hearts are premature atrial contractions (PAC’s), atrial flutter, atrioventricular reentry tachycardia (AVRT), permanent junctional reciprocating tachycardia (PJRT), ventricular tachycardia, and heart block. Neonatal heart block is associated with maternal autoimmune disease, i.e., systemic lupus. Post-operative Arrhythmias Early post-operative arrhythmias usually seen are sinus tachycardia, sinus bradycardia, SVT, JET, complete AV block, and less frequently ventricular tachycardia. Post-operative arrhythmias result from manipulation or injury of the conduction system. The site of surgical repair may increase the risk of certain types of arrhythmias observed. Late post operative arrhythmias such as atrial flutter, and/or intraatrial reentrant tachycardia are seen months to years after surgery. These arrhythmias are observed more often with Fontan, Mustard, Senning and tetralogy of Fallot repairs. These tachyarrhythmias can result in poor ventricular function and decreased quality of life. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 29 Common late post operative arrhythmias include atrial tachycardia, which may be seen in 50% of Fontan patients and tend to recur after a period of time. Arrhythmias associated with specific congenital cardiac malformations are highlighted in this section.4,28,17 Aortic Arch with VSD Severe Aortic Stenosis/ Aortic Valve Surgery JET Myocardial ischemia from severe left ventricular outflow obstruction, LV hypertrophy and strain resulting in ventricular arrhythmias. Conduction abnormalities and complete heart block may be seen post surgical resection of sub-aortic obstructive tissue. Although remote to the conduction system, junctional tachycardia may occur. Prone to VT. Atrial Septal Defect (ASD) Sinus node dysfunction and transient atrial arrhythmias, atrial flutter, atrial fibrillation, ventricular tachycardias. Atrioventricular Septal Defect (AVSD) Transient and permanent sinus node dysfunction, supraventricular arrhythmias; JET; AV block; and VT. Grosse-Wortmann, et al., found that complete AV block was more common post operative repair of complete AVSD. Congenitally Corrected Transposition of the Great Arteries (cc-TGA/ L-TGA) Accessory pathways; AV Block: 2nd & 3rd degree; ventricular ectopy. Congenital AV block may preexist due to intrinsic structural malformation. Cor–Triatriatum Sinus bradycardia, atrial tachyarrhythmias, AV conduction disturbances D-Transposition of the Great Arteries (D-TGA) Sinus bradycardia, sinoatrial block, junctional rhythm, JET, premature atrial contractions, Mobitz 1, VT. Prone to VT if repaired with atrial level switch procedures, Senning or Mustard. Late complications of arrhythmias in the Jatene arterial switch procedure are rare. Late complications of atrial switch (Senning/Mustard) are that greater than 50% of patients have serious arrhythmias. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 30 Ebstein’s Anomaly of the Tricuspid Valve Common to have rhythm disturbances related to atrial and ventricular dilatation and conduction disturbances: accessory pathways; WPW and VT, SVT, atrial fibrillation, atrial flutter; 1st degree heart block and rarely 3rd degree heart block. Congenital accessory pathways such as WPW may preexist due to intrinsic structural malformation. Heart Transplant Intraatrial reentrant tachycardia, AET. Sinus bradycardia, AV block in a small percentage of children. Supraventricular and ventricular arrhythmias are relatively uncommon and may indicate rejection. Pulmonary Atresia with Intact Ventricular Septum Pulmonary Atresia with a VSD Single Ventricle Hypoplastic Left Heart Syndrome (HLHS) Single Ventricle – Bidirectional Cavopulmonary (Glenn) Connection Single Ventricle – Fontan Rare rhythm disturbances observed. Ventricular arrhythmias if coronary sinusoids with ischemia. Tetralogy of Fallot (TOF) Total Anomalous Pulmonary Venous Return (TAPVR) Truncus Arteriosus Tricuspid Atresia Ventricular Septal Defect (VSD) Sometimes AV conduction abnormalities observed. Atrial arrhythmias. Transient sinus node dysfunction. Sinus node dysfunction, atrial reentrant tachycardia: atrial flutter, atrial fibrillation, intra-atrial tachycardia, VT. Early or late SVT, junctional rhythm, accelerated junctional rhythm and VT. Sinus node dysfunction, supraventricular tachycardias – atrial flutter, accelerated junctional rhythm, JET, AV blocks, VT. Right bundle branch block (RBBB). Prone to VT due to the volume loading on the RV causing RV dilation, failure, and increased right sided pressures. Predisposes patient to SCD. Atrial arrhythmias, JET, sinus bradycardia, AV conduction disturbances. AV conduction disturbances; ventricular arrhythmias due to the right ventriculotomy. Supraventricular arrhythmias; atrial ectopy, flutter, fibrillation. Junctional rhythm, accelerated junctional rhythm, JET, VT (Grosse-Wortmann, 2010), AV conduction block. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 31 Inherited Cardiomyopathies Genetic predisposition to cardiac arrhythmias with an increased risk of sudden cardiac death are reviewed in the section below.1,7 CARDIOMYOPATHIES PATHOPHYSIOLOGY CARDIAC ARRHYTHMIAS VT, SCD. Hypertrophic Cardiomyopathy (HCM) Hypertrophic myocardium with asymmetric septal hypertrophy. Dilated Cardiomyopathy (DCM) Dilated poorly contractile ventricles. SVT, VT, SCD. Arrhythmogenic Right Ventricular (RV) Cardiomyopathy (ARVC) or Dysplasia A form of dilated cardiomyopathy. Fibrofatty replacement of the RV wall myocytes and patchy areas of fibrosis with progressive RV dysfunction and enlargement. RV tachyarrhythmias with variable response to beta-blockers and to catheter ablation. Channelopathies – Electrical Myopathies:8,36 CARDIOMYOPATHIES Long QT Syndrome (LQTS) PATHOPHYSIOLOGY Identified by prolonged QT interval corrected for heart rate (QTc). QT interval greater than 0.46 seconds, with upper normal limit of 0.44 seconds. CARDIAC ARRHYTHMIAS High risk of bursts of VT such as runs of Torsades de Pointes, progressing to VF and SCD. May present with syncope, seizures or SCD. Acquired or congenital; can be secondary due to drugs, i.e., amiodarone, procainamide, sotolol, tricyclic antidepressants and/or electrolyte imbalance (hypokalemia, hypomagnesemia). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 32 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Polymorphic ventricular tachycardia. CPVT is initiated by stimulation of the adrenergic receptors from stress, emotion or exertion/physical activity; found in normal hearts with normal coronary arteries and normal ECG’s. VT, ventricular fibrillation, and SCD. Brugada Syndrome (BrS) Autosomal dominant genetic In 20% of cases, mutations in the sodium channel are thought to be causative. History of ventricular arrhythmias – ventricular fibrillation, syncope and SCD. Marked by RBBB and striking ST elevation in V1-V3. ECG manifestation and arrhythmias most likely during times of fever. PATHOPHYSIOLOGY CARDIAC Inflammatory Disease:8 ACQUIRED ARRHYTHMIAS Myocarditis Viral myocarditis is a cell mediated immunologic reaction. Myocardium may have lymphocyte infiltration, necrosis and scarring. Myocarditis may lead to cardiomegaly and congestive heart failure, hemodynamic compromise, shock and death. Cells undergo lymphocyte infiltration, necrosis and scarring. Risk SCD from VT and AV block. Clinical Evaluation Of The Pediatric Patient The following components of clinical assessment are necessary when a health provider approaches the pediatric patient to evaluate for a cardiac arrhythmia. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 33 Review of Family History Family history should be reviewed, such as heart disease, death at young age, sudden death, and seizures. Additionally, neonatal history, child’s personal history of syncope, palpitations, racing heart beat, seizures, exercise intolerance, family, feeding intolerance; and, genetics, congenital cardiac malformations, diagnostic investigations, previous surgical repair and post-surgical anatomy should be pursued in the history taking. The provider should inquire about events preceding rhythm disturbance. Clinical Assessment Irritability, feeding intolerance, respiratory distress, tachycardia or bradycardia for age, irregular heart rate/pulse, decreased capillary refill time, lethargy, congestive heart failure, decreased level of consciousness, syncope, absent pulses/cardiac arrest should be assessed. The clinician needs to be familiar with normal heart rate for different ages. Infants generally have heart rates greater than 80 beats/min and less than 170 beats/min. Children usually have heart rates greater than 60 beats/min and less than 140 beats/min. Heart rates above these ranges are concerning and warrant further assessment. Consider the appropriate heart rate response for physiology. Cardiac assessment includes auscultation of heart sounds for murmurs, extra heart sounds, abnormal activity of the precordium palpation for heaves and thrills, assessment of perfusion, pulses, capillary refill time, blood pressure and assessment of vital signs. Cutaneous saturation or pulse oxymetry is part of the nursece4less.com nursece4less.com nursece4less.com nursece4less.com 34 cardiorespiratory assessment and should be assessed. Identify tolerance of the arrhythmia through assessment of clinical symptoms. Profound hemodynamic effects may result from loss of AV synchrony such as JET, AET or AV block, heart rate that is too slow or too fast, VT or VF. This is worse in the context of preexisting myocardial dysfunction or palliated physiology. A rapid heart rate results in decreased diastolic and coronary artery filling times.18 Diagnostic Evaluation This section outlines diagnostic tests that may be considered in order to ensure an accurate diagnosis and impact of arrhythmia.12 Recording baseline pre-operative and post-operative rhythm strips is optimal. Any Abnormal ECG’s should be compared to baseline. Document the rhythm disturbance by a 12 or 15 lead pediatric electrocardiogram. Pediatric 15 Lead ECG includes right-sided leads V4R, V5R, V6R. This can be invaluable in accurate identification of the type of arrhythmia. The patient should be monitored continuously. A Holter electrocardiogram (usually 24 hour ambulatory) may be of value in identification of the arrhythmia events. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 35 Perform an atrial electrocardiogram using the atrial pacing wire in post cardiac surgical patients, where P waves cannot be clearly identified. It can be helpful to capture electrical evidence of termination of the tachycardia on a 15 lead ECG or rhythm strip. Test blood levels of potassium, calcium and magnesium; and, thyroid function tests, complete blood count, and toxicology screen. Electrolyte imbalances are often associated with rhythm disturbances. If suspicious of myocarditis or with worsening cardiac function check viral etiologies. Cardiac enzymes, such as troponin levels and CPK-MB are markers of myocardial injury. A chest X-ray may demonstrate enlargement of the heart. Echocardiogram (ECHO) provides a qualitative and quantitative evaluation of cardiac function to rule out underlying structural heart disease, thrombus formation and ventricular dysfunction. A quantitative value of ejection fraction can be reported. Use of pharmacological agents such as adenosine and procainamide can assist with diagnosis of arrhythmias. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 36 Exercise testing may be used to provoke and diagnose arrhythmias and associated symptoms. A catecholamine challenge or transoesophageal pacing can also be used to provoke arrhythmias in a controlled environment. Invasive electrophysiology studies with cardiac catheterization help to identify ectopic foci and accessory pathways, which can be mapped and ablated. 12-lead ECG The ECG is conventionally recorded at a speed of 25 mm/s and at a calibration of 1 cm = 1 mV. A standard 12-lead ECG includes three standard (bipolar) limb leads – I, II, and III – three augmented unipolar limb leads – aVR, aVL, and aVF – and six unipolar chest leads – V1–V6. Accurate positioning of the leads (especially the chest leads) is important. V1 and V2 are in the fourth intercostal space, V4 is in the fifth intercostal space in the midclavicular line, V5 is in the anterior axillary line, and V6 in the midaxillary line, both these last two horizontal to V4. Routine evaluation of an ECG involves assessment of the heart rate, heart rhythm, and QRS axis, then the P waves, QRS complexes, T waves, and measurement of the PR, QRS, and QT intervals. Many modern ECG machines automatically measure and display many of these variables. The measurements are usually accurate and reliable nursece4less.com nursece4less.com nursece4less.com nursece4less.com 37 but a machine-derived interpretation of the ECG should be treated with some caution, even if produced by a pediatric algorithm. The machine often distinguishes between normality and abnormality fairly accurately (assuming that the age of the patient is entered into the algorithm) but analysis of the type of arrhythmia is often unreliable. Whenever possible, a 12-lead ECG recording in sinus rhythm and during symptoms should be obtained in children with suspected or proven arrhythmia.18 Rhythm Strips Rhythm strips are most useful in documenting changes in rhythm in response to interventions such as adenosine administration, but they should not be seen as an alternative to recording a 12-lead ECG. Rhythm strips usually contain three leads but, on some machines, there may be six, twelve, or only one. The leads selected vary. Leads I, aVF, and V1 are a good combination but others may be preferred after examining the 12-lead ECG.19 Holter Monitoring/Ambulatory ECG Recording Holter monitoring, or ambulatory ECG recording, has become a standard test in the investigation and follow-up of children with suspected or proven arrhythmias. It is well tolerated and particularly useful in children with fairly frequent symptoms, suggesting that there is a reasonable chance of recording the ECG during symptoms. It is also valuable in assessing response to treatment in children with incessant tachycardias, congenital long QT syndrome, etc.20 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 38 ECG Event Recorders Event recorders are carried by children or their parents but are not necessarily worn all the time. They can be used in loop mode (where they are worn constantly and a button is pressed during symptoms to make a record of the ECG) or event mode (when the recorder is applied and a recording made when symptoms occur).21 Exercise ECG Treadmill or bicycle exercise ECG recording is sometimes helpful in investigation of arrhythmias but is useful in providing reassurance for children and their families in the presence of exercise-related symptoms thought not to be due to arrhythmia. Exercise-induced arrhythmias are unusual but are sometimes seen in AV re-entry. The exercise test is very helpful in suspected catecholaminergic polymorphic ventricular tachycardia. Implanted Loop Recorder In children with worrying syncope but no proven diagnosis, an implanted loop recorder may be very helpful. The device has a 3-year battery and is inserted subcutaneously in the left axilla or on the left anterior chest wall. It works in loop mode and can be programmed to store recordings of arrhythmias, which have rates below or above preset limits. Children or their parents or teachers using an external activating device can also trigger a recording. The yield from this type of recorder depends on the selectivity of the physician but it can be most useful in children with infrequent major syncope. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 39 Transesophageal Electrophysiology Study The transesophageal electrophysiology study is not widely employed in pediatric practice because of its limited physical acceptability. It involves (per oral or per nasal) positioning of a pacing wire in the esophagus behind the left atrium. Pacing in this position can usually capture the atria but requires a higher output stimulator than a normal pacing box. Transesophageal pacing can be used in neonates to overdrive atrial flutter or atrioventricular tachycardia, but its use in older children is limited by discomfort and it often requires general anesthesia. It has been advocated for investigation of children with symptoms of palpitation, elucidation of arrhythmia mechanism if tachycardia is documented on ambulatory ECG monitoring, and “risk assessment” in asymptomatic children with a Wolff–Parkinson–White pattern on the ECG. It is perhaps more widely used in some European countries than in the U.K., the U.S., or elsewhere.22 Tilt Test A head-up tilt test is sometimes used for investigation of children older than 6 years with recurrent syncope or presyncope. Protocols vary but all involve the child lying horizontal for 15–20 min before being passively tilted to an angle of 60–80 for up to 45 min or until the development of symptoms. The ECG and blood pressure are recorded continuously. Fainting or a feeling of faintness is usually accompanied by bradycardia and hypotension, and the child is rapidly returned to the horizontal. Less commonly there is a hypotensive response without bradycardia. The most unusual response is cardioinhibitory with bradycardia or asystole before syncope.8 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 40 A “positive” test response with passive tilting is observed in 40–50% of children with a good history suggesting neurally mediated syncope. The sensitivity is increased by infusion of isoprenaline (isoproterenol) but specificity is reduced. False positives and false negatives limit the usefulness of the test, but it can be helpful in management of syncope.2 Common Treatments The need for treatment of arrhythmias depends on the symptoms and the seriousness of the arrhythmia. Treatment is directed at causes. If necessary, direct antiarrhythmic therapy, including antiarrhythmic drugs, cardioversion-defibrillation, implantable cardioverterdefibrillators (ICDs), pacemakers (and a special form of pacing, cardiac resynchronization therapy), or a combination, is used. Drugs for Arrhythmias Antiarrhythmic drugs comprise many different drug classes and have several different mechanisms of action. Furthermore, some classes and even some specific drugs within a class are effective with only certain types of arrhythmias. Therefore, attempts have been made to classify the different antiarrhythmic drugs so by mechanism. Although different classification schemes have been proposed, the first scheme (Vaughan-Williams) is still the one that most physicians use when speaking of antiarrhythmic drugs. The following list shows the Vaughan-Williams classification and the basic mechanism of action associated with each class. Note that Class I drugs are further broken down into subclasses because of subtle, nursece4less.com nursece4less.com nursece4less.com nursece4less.com 41 yet important differences in their effects on action potentials. Most antiarrhythmic drugs are grouped into 4 main classes (Vaughan Williams classification) based on their dominant cellular electrophysiologic effect.38 Class I Drugs Class I drugs are subdivided into subclasses a, b, and c. Class I drugs are sodium channel blockers (membrane-stabilizing drugs) that block fast sodium channels, slowing conduction in fast-channel tissues (working atrial and ventricular myocytes, His-Purkinje system). Class II Drugs Class II drugs are beta-blockers, which affect predominantly slowchannel tissues (sinoatrial [SA] and atrioventricular [AV] nodes), where they decrease rate of automaticity, slow conduction velocity, and prolong refractoriness. Class III Drugs Class III drugs are primarily potassium channel blockers, which prolong action potential duration and refractoriness in slow- and fastchannel tissues. Class IV Drugs Class IV drugs are the nondihydropyridine calcium channel blockers, which depress calcium-dependent action potentials in slow-channel tissues and thus decrease the rate of automaticity, slow conduction velocity, and prolong refractoriness. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 42 Digoxin and adenosine are not included in the Vaughan Williams classification. Digoxin shortens atrial and ventricular refractory periods and is vagotonic, thereby prolonging AV nodal conduction and AV nodal refractory periods. Adenosine slows or blocks AV nodal conduction and can terminate tachyarrhythmias that rely upon AV nodal conduction for their perpetuation. The Vaughan-Williams classification has severe limitations. When initially conceived, there were relatively few antiarrhythmic drugs and our understanding of their mechanisms was rudimentary at best. Now with many more antiarrhythmic drugs, and with a much greater yet still incomplete understanding of drug mechanisms, this classification system breaks down especially for the Class I and III drugs. Many of these drugs have mechanisms of action that are shared with drugs found the other classes. For example, amiodarone, a Class III antiarrhythmic, also has sodium and calcium-channel blocking actions. Many of the Class I compounds also affect potassium channels. Some of these drugs, it could be argued, could fit in just as well as a different class than the one that they may be assigned. For this reason, different sources of information may classify some antiarrhythmic drugs differently than other sources.78,79 The drugs that make up the different classes differ in their efficacy (and sometimes safety) for different types of arrhythmias. The following table provides an overview of drug classes and associated arrhythmias. Antiarrhythmic agents that are not included in the Vaughan-Williams scheme are also shown in the table.24 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 43 Condition Sinus tachycardia Atrial fibrillation/flutter Drug Class II, IV treatment Ventricular rate control is III, IV important goal; anticoagulation is digitalis required Class IA, IC, II, supraventricular III, IV tachycardia adenosine AV block Atropine Ventricular tachycardia Class I, II, III complexes Other underlying causes may need Class IA, IC, II, Paroxysmal Premature ventricular Comments Class II, IV magnesium sulfate Acute reversal PVCs are often benign and do not require treatment Class IB Digitalis toxicity magnesium sulfate Class I Antiarrhythmic Drugs Sodium channel blockers (membrane-stabilizing drugs) block fast sodium channels, slowing conduction in fast-channel tissues (working atrial and ventricular myocytes, His-Purkinje system). In the ECG, this effect may be reflected as widening of the P wave, widening of the QRS complex, prolongation of the PR interval, or a combination. Class I drugs are subdivided based on the kinetics of the sodium channel effects: nursece4less.com nursece4less.com nursece4less.com nursece4less.com 44 Class Ib drugs have fast kinetics. Class Ic drugs have slow kinetics. Class Ia drugs have intermediate kinetics. The kinetics of sodium channel blockade determine the heart rates at which their electrophysiologic effects become manifest. Because class Ib drugs have fast kinetics, they express their electrophysiologic effects only at fast heart rates. Thus, an ECG obtained during normal rhythm at normal rates usually shows no evidence of fast-channel tissue conduction slowing. Class Ib drugs are not very potent antiarrhythmics and have minimal effects on atrial tissue. Because class Ic drugs have slow kinetics, they express their electrophysiologic effects at all heart rates. Thus, an ECG obtained during normal rhythm at normal heart rates usually shows fastchannel tissue conduction slowing. Class Ic drugs are more potent antiarrhythmics. Because class Ia drugs have intermediate kinetics, their fast-channel tissue conduction slowing effects may or may not be evident on an ECG obtained during normal rhythm at normal rates. Class Ia drugs also block repolarizing potassium channels, prolonging the refractory periods of fast-channel tissues. On the ECG, this effect is reflected as QT-interval prolongation even at normal rates. Class Ib drugs and class Ic drugs do not block potassium channels directly.62,79 The kinetics of sodium channel blockade determine the heart rates at which their electrophysiologic effects become manifest. The primary indications are supraventricular tachycardia (SVT) for class Ia and Ic drugs and ventricular tachycardia (VTs) for all class I nursece4less.com nursece4less.com nursece4less.com nursece4less.com 45 drugs. Adverse effects of class I drugs include proarrhythmia, a drugrelated arrhythmia worse than the arrhythmia being treated, which is the most worrisome adverse effect. All class I drugs may worsen VTs. Class I drugs also tend to depress ventricular contractility. Because these adverse effects are more likely to occur in patients with a structural heart disorder, class I drugs are not generally recommended for such patients. Thus, these drugs are usually used only in patients who do not have a structural heart disorder or in patients who have a structural heart disorder but who have no other therapeutic alternatives. There are other adverse effects of class I drugs that are specific to the subclass or individual drug.14,17,78,80 Class Ia Antiarrhythmic Drugs Class Ia drugs have kinetics that are intermediate between the fast kinetics of class Ib and the slow kinetics of class Ic. Their fastchannel tissue conduction slowing effects may or may not be evident on an ECG obtained during normal rhythm at normal rates. Class Ia drugs block repolarizing potassium channels, prolonging the refractory periods of fast-channel tissues. On the ECG, this effect is reflected as QT-interval prolongation even at normal rates.61 Class Ia drugs are used for suppression of atrial premature beats (APB), ventricular premature beats (VPB), supraventricular and ventricular tachycardias, atrial fibrillation (AF), atrial flutter, and ventricular fibrillation. The primary indications are supraventricular and ventricular tachycardias. Class Ia drugs may cause torsades de pointes ventricular tachycardia. Class Ia drugs may organize and slow nursece4less.com nursece4less.com nursece4less.com nursece4less.com 46 atrial tachyarrhythmias enough to permit 1:1 AV conduction with marked acceleration of the ventricular response rate.62 Class Ib Antiarrhythmic Drugs Class Ib drugs have fast kinetics; they express their electrophysiologic effects only at fast heart rates. Thus, an ECG obtained during normal rhythm at normal rates usually shows no evidence of fast-channel tissue conduction slowing. Class Ib drugs are not very potent antiarrhythmics and have minimal effects on atrial tissue. Class Ib drugs do not block potassium channels directly. Class Ib drugs are used for the suppression of ventricular arrhythmias (ventricular premature beats, ventricular tachycardia, ventricular fibrillation).38 Class Ic Antiarrhythmic Drugs Class Ic drugs have slow kinetics; they express their electrophysiologic effects at all heart rates. Thus, an ECG obtained during normal rhythm at normal heart rates usually shows fastchannel tissue conduction slowing. Class Ic drugs are more potent antiarrhythmics than either class Ia or class Ib drugs. Class Ic drugs do not block potassium channels directly. Class Ic drugs may organize and slow atrial tachyarrhythmias enough to permit 1:1 AV conduction with marked acceleration of the ventricular response rate. Class Ic drugs are used for suppression of atrial and ventricular premature beats, supraventricular and ventricular tachycardias, atrial fibrillation, atrial flutter, and ventricular fibrillation. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 47 Class II Antiarrhythmic Drugs Class II antiarrhythmic drugs are beta-blockers, which affect predominantly slow-channel tissues (SA and AV nodes), where they decrease rate of automaticity, slow conduction velocity, and prolong refractoriness. Thus, heart rate is slowed, the PR interval is lengthened, and the AV node transmits rapid atrial depolarizations at a lower frequency.68 Class II drugs are used primarily to treat SVTs, including sinus tachycardia, AV nodal reentry, AF, and atrial flutter. These drugs are also used to treat VTs to raise the threshold for ventricular fibrillation (VF) and reduce the ventricular proarrhythmic effects of betaadrenoceptor stimulation.80 Beta-blockers are generally well tolerated; adverse effects include lassitude, sleep disturbance, and GI upset. These drugs are contraindicated in patients with asthma. Class III Antiarrhythmic Drugs Class III drugs are membrane stabilizing drugs, primarily potassium channel blockers, which prolong action potential duration and refractoriness in slow- and fast-channel tissues. Thus, the capacity of all cardiac tissues to transmit impulses at high frequencies is reduced, but conduction velocity is not significantly affected. Because the action potential is prolonged, rate of automaticity is reduced. The predominant effect on the ECG is QT-interval prolongation. These drugs are used to treat SVTs and VTs. Class III drugs have a risk of ventricular proarrhythmia, particularly torsades de pointes VT and are not used in patients with torsades de pointes VT.61,82 nursece4less.com nursece4less.com nursece4less.com nursece4less.com 48 Class IV Antiarrhythmic Drugs Class IV drugs are the nondihydropyridine calcium channel blockers, which depress calcium-dependent action potentials in slow-channel tissues and thus decrease the rate of automaticity, slow conduction velocity, and prolong refractoriness. Heart rate is slowed, the PR interval is lengthened, and the AV node transmits rapid atrial depolarizations at a lower frequency. These drugs are used primarily to treat SVTs. They may also be used to slow rapid atrial fibrillation or atrial flutter. One form of VT (left septal or Belhassen VT) can be treated with verapamil.30 The following table provides specific information about each drug used to treat arrhythmias in children.17,24,30,54,79,80 Amiodarone Life-threatening arrhythmias (tablet): Amiodarone is intended for use only in patients with indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity. Potentially fatal toxicities (tablet): Amiodarone has several potentially fatal toxicities, the most important of which is pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 10% to 17% in some series of patients with ventricular arrhythmias given doses of approximately 400 mg/day, and as abnormal diffusion capacity without symptoms in a much higher percentage of patients. Pulmonary toxicity has been fatal approximately 10% of the time. Liver injury is common with amiodarone, but is usually mild and evidenced only by abnormal liver enzymes. However, overt liver disease can occur and has been fatal in a few cases. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 49 Like other antiarrhythmics, amiodarone can exacerbate the arrhythmia (e.g., by making the arrhythmia less well tolerated or more difficult to reverse). This has occurred in 2% to 5% of patients in various series, and significant heart block or sinus bradycardia has been seen in 2% to 5%. In most cases, all of these events should be manageable in the proper clinical setting. Although the frequency of such proarrhythmic events does not appear greater with amiodarone than with many other agents used in this population, the effects are prolonged when they occur. High-risk patients (tablet): Even in patients at high risk of arrhythmic death in whom the toxicity of amiodarone is an acceptable risk, amiodarone poses major management problems that could be life-threatening in a population at risk of sudden death; therefore, make every effort to utilize alternative agents first. The difficulty of using amiodarone effectively and safely poses a significant risk to patients. Patients with the indicated arrhythmias must be hospitalized while the loading dose of amiodarone is given, and a response generally requires at least 1 week, usually 2 weeks or more. Because absorption and elimination are variable, maintenance dose selection is difficult, and it is not unusual to require dosage decrease or discontinuation of treatment. In a retrospective survey of 192 patients with ventricular tachyarrhythmias, 84 patients required dose reduction and 18 required at least temporary discontinuation because of adverse reactions, and several series have reported 15% to 20% overall frequencies of discontinuation because of adverse reactions. The time at which a previously controlled life-threatening arrhythmia will recur after discontinuation or dose adjustment is unpredictable, ranging from weeks to months. The patient is obviously at great risk during this time and may need prolonged hospitalization. Attempts to substitute other antiarrhythmic agents when amiodarone must be stopped will be made difficult by the gradually, but unpredictably, changing amiodarone body burden. A similar problem exists when amiodarone is not effective; it still poses the risk of an interaction with whatever subsequent treatment is tried. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 50 Brand Names: Cordarone Nexterone Pacerone Pharmacologic Category Antiarrhythmic Agent, Class III Dosage: Pulseless VT or VF (PALS dosing): Infants, Children, and Adolescents IV, I.O.: 5 mg/kg (maximum: 300 mg per dose) rapid bolus; may repeat twice up to a maximum total dose of 15 mg/kg during acute treatment (PALS 2010). Perfusing tachycardias (PALS dosing): Infants, Children, and Adolescents - IV, I.O.: Loading dose: 5 mg/kg (maximum: 300 mg per dose) over 20 to 60 minutes; may repeat twice up to maximum total dose of 15 mg/kg during acute treatment (PALS 2010). Nadolol Exacerbation of ischemic heart disease following abrupt withdrawal: Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing nadolol administered long term, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1 to 2 weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstitute nadolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without the health care provider's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly, even in patients treated only for hypertension. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 51 Brand Names: Corgard Pharmacologic Category Antianginal Agent Antihypertensive Beta-Blocker, Nonselective Sotalol Proarrhythmic effects: To minimize the risk of induced arrhythmia, patients initiated or reinitiated on sotalol or sotalol AF and patients who are converted from IV to oral administration should be placed for a minimum of 3 days (on their maintenance dose) in a facility that can provide cardiac resuscitation, continuous electrocardiographic (ECG) monitoring, and calculations of creatinine clearance (CrCl). Sotalol injection and oral solution (Sotylize): Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. Do not initiate sotalol therapy if the baseline QTc is longer than 450 msec. If the QT interval prolongs to 500 msec or greater, the dose must be reduced, the interval between doses prolonged, the duration of the infusion prolonged (sotalol injection), or the drug discontinued. Adjust the dosing interval based on CrCl. Renal impairment: Calculate CrCl prior to dosing. Product interchange: Do not substitute sotalol for sotalol AF because of significant differences in labeling (i.e., patient package insert, dosing administration, safety information). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 52 Brand Names: Betapace Betapace AF Sorine Sotylize Pharmacologic Category Antiarrhythmic Agent, Class II Antiarrhythmic Agent, Class III Beta-Blocker, Nonselective Dosing: Baseline QTc interval and creatinine clearance must be determined prior to initiation. If CrCl ≤60 mL/minute, dosing interval adjustment is necessary. Sotalol should be initiated and doses increased in a hospital for at least 3 days with facilities for cardiac rhythm monitoring and assessment. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment. (Note: Dosing per manufacturer, based on pediatric pharmacokinetic data; wait at least 36 hours between dosage adjustments to allow monitoring of QTc intervals). Atrial fibrillation/flutter (symptomatic): Oral: Betapace AF, Sotylize Infants and Children ≤2 years: Dosage should be adjusted (decreased) by plotting of the child's age on a logarithmic scale; see graph or refer to manufacturer's package labeling. Children >2 years and Adolescents: Initial: 90 mg/m2/day in 3 divided doses; may be incrementally increased to a maximum of 180 mg/m 2/day Ventricular arrhythmias: Oral: Betapace, Sorine, Sotylize Infants and Children ≤2 years: Dosage should be adjusted (decreased) by plotting of the child's age on a logarithmic scale; see graph or refer to manufacturer's package labeling. Children >2 years and Adolescents: Initial: 90 mg/m2/day in 3 divided doses; may be incrementally increased to a maximum of 180 mg/m 2/day. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 53 Adenosine Brand Names: Adenocard Adenoscan Pharmacologic Category Antiarrhythmic Agent, Miscellaneous Diagnostic Agent Dosing: Rapid IV push (over 1 to 2 seconds) via peripheral line, followed by a normal saline flush. Paroxysmal supraventricular tachycardia (Adenocard): Infants and Children - IV: Manufacturer's labeling: Children <50 kg: Initial: 0.05 to 0.1 mg/kg (maximum initial dose: 6 mg). If conversion of PSVT does not occur within 1 to 2 minutes, may increase dose by 0.05 to 0.1 mg/kg. May repeat until sinus rhythm is established or to a maximum single dose of 0.3 mg/kg or 12 mg. Follow each dose with normal saline flush. Children ≥50 kg: Refer to adult dosing. Pediatric advanced life support: Treatment of SVT: IV, I.O.: Initial: 0.1 mg/kg (maximum initial dose: 6 mg); if not effective within 1 to 2 minutes, administer 0.2 mg/kg (maximum single dose: 12 mg). Follow each dose with ≥5 mL normal saline flush. Diltiazem Brand Names: Cardizem Cardizem CD Cardizem LA nursece4less.com nursece4less.com nursece4less.com nursece4less.com 54 Cartia XT Dilacor XR [DSC] Dilt-CD [DSC] Dilt-XR Diltiazem CD Diltiazem HCl CD [DSC] Diltzac [DSC] Matzim LA Taztia XT Tiazac Pharmacologic Category Antianginal Agent Antiarrhythmic Agent, Class IV Antihypertensive Calcium Channel Blocker Calcium Channel Blocker, Nondihydropyridine Dosing: Children: Minimal information available; some centers use the following: Hypertension (off-label use): Oral: Initial: 1.5-2 mg/kg/day in 3 divided doses (maximum: 6 mg/kg/day, up to 360 mg daily). Adolescents Angina: Oral: Capsule, extended release: Dilacor XR, Dilt-XR: Initial: 120 mg once daily; titrate over 7 to 14 days; usual dose range - 120 to 320 mg daily: maximum: 480 mg daily. Cardizem CD, Cartia XT: Initial: 120 to 180 mg once daily; titrate over 7 to 14 days; usual dose range: 120 to 320 mg daily; maximum: 480 mg daily. Tiazac, Taztia XT: Initial: 120 to 180 mg once daily; titrate over 7 to 14 days; usual dose range - 120 to 320 mg daily; maximum: 540 mg daily. Tablet, extended release (Cardizem LA, Matzim LA, Tiazac XC [Canadian product]): 180 mg once daily; may increase at 7- to 14-day intervals; usual dose range: 120 to 320 mg/day; maximum: 360 mg daily. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 55 Tablet, immediate release (Cardizem): Usual starting dose: 30 mg 4 times daily; titrate dose gradually at 1- to 2-day intervals; usual dose range: 120 to 320 mg daily in 4 divided doses. Hypertension: Oral: Capsule, extended release (once-daily dosing): Cardizem CD, Cartia XT: Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range: 240 to 360 mg daily; maximum: 480 mg daily Dilacor XR, Dilt-XR: Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range: 240 to 360 mg daily; maximum: 540 mg daily. Tiazac, Taztia XT: Initial: 120 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range: 240 to 360 mg daily; maximum: 540 mg daily. Capsule, extended release (twice-daily dosing): Initial: 60 to 120 mg twice daily; dose adjustment may be made after 14 days; usual range: 240 to 360 mg daily. Note: Diltiazem is available as a generic intended for either once- or twicedaily dosing, depending on the formulation; verify appropriate extended release capsule formulation is administered. Tablet, extended release (Cardizem LA, Matzim LA, Tiazac XC [Canadian product]): Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range: 240-360 mg daily; maximum: 540 mg daily. Atrial fibrillation, atrial flutter, PSVT: Initial IV bolus dose: 0.25 mg/kg actual body weight over 2 minutes (average adult dose: 20 mg); ACLS guideline recommends 15 to 20 mg. Repeat bolus dose (may be administered after 15 minutes if the response is inadequate): 0.35 mg/kg actual body weight over 2 minutes (average adult dose: 25 mg); ACLS guideline recommends 20 to 25 mg. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 56 Continuous infusion (infusions >24 hours or infusion rates >15 mg/hour are not recommended): Initial infusion rate of 10 mg/hour; rate may be increased in 5 mg/hour increments up to 15 mg/hour as needed; some patients may respond to an initial rate of 5 mg/hour. If diltiazem injection is administered by continuous infusion for >24 hours, the possibility of decreased diltiazem clearance, prolonged elimination halflife, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered. Atrial fibrillation (rate control) (off-label use): Oral: Extended release (capsule or tablet): Usual maintenance dose: 120 to 360 mg once daily. Conversion from IV diltiazem to oral diltiazem: Oral dose (mg daily) is approximately equal to [rate (mg/hour) x 3 + 3] x 10. 3 mg/hour = 120 mg daily 5 mg/hour = 180 mg daily 7 mg/hour = 240 mg daily 11 mg/hour = 360 mg daily Atenolol Advise patients with coronary artery disease who are being treated with atenolol against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction (MI) and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of atenolol is planned, observe the patient carefully and advise the patient to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly, even in patients treated only for hypertension. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 57 Brand Names: Tenormin Pharmacologic Category Antianginal Agent Antihypertensive Beta-Blocker, Beta-1 Selective Dosing: Hypertension: Oral: Children: 0.5 to 1 mg/kg/dose given daily; range of 0.5 to 1.5 mg/kg/day; maximum dose: 2 mg/kg/day up to 100 mg/day. Esmolol Brand Names: Brevibloc Brevibloc in NaCl Pharmacologic Category Antiarrhythmic Agent, Class II Antihypertensive Beta-Blocker, Beta-1 Selective Dosing: Intraoperative and postoperative tachycardia and/or hypertension: Immediate control: Initial IV bolus: 1 mg/kg over 30 seconds, followed by a 150 mcg/kg/minute infusion, if necessary. Adjust infusion rate as needed to maintain desired heart rate and/or blood pressure (up to 300 mcg/kg/minute) Gradual control: Initial bolus: 0.5 mg/kg over 1 minute, followed by a 50 mcg/kg/minute infusion for 4 minutes. Infusion may be continued at 50 mcg/kg/minute or, if the response is inadequate, titrated upward in 50 mcg/kg/minute increments (increased no more frequently than every 4 minutes) to a maximum of 300 mcg/kg/minute; may administer an optional loading dose equal to the initial bolus (0.5 mg/kg over 1 minute) prior to each increase in infusion rate. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 58 For control of tachycardia, doses >200 mcg/kg/minute provide minimal additional effect. For control of postoperative hypertension, as many as onethird of patients may require higher doses (250-300 mcg/kg/minute) to control blood pressure; the safety of doses >300 mcg/kg/minute has not been studied. Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia: IV Loading dose (optional): 0.5 mg/kg over 1 minute; follow with a 50 mcg/kg/minute infusion for 4 minutes; response to this initial infusion rate may be a rough indication of the responsiveness of the ventricular rate. Infusion may be continued at 50 mcg/kg/minute or, if the response is inadequate, titrated upward in 50 mcg/kg/minute increments (increased no more frequently than every 4 minutes) to a maximum of 200 mcg/kg/minute. To achieve more rapid response, following the initial loading dose and 50 mcg/kg/minute infusion, rebolus with a second 0.5 mg/kg loading dose over 1 minute, and increase the maintenance infusion to 100 mcg/kg/minute for 4 minutes. If necessary, a third (and final) 0.5 mg/kg loading dose may be administered, prior to increasing to an infusion rate of 150 mcg/kg/minute. After 4 minutes of the 150 mcg/kg/minute infusion, the infusion rate may be increased to a maximum rate of 200 mcg/kg/minute (without a bolus dose). (Note: If a loading dose is not administered, a continuous infusion at a fixed dose reaches steady-state in ~30 minutes. In general, the usual effective dose is 50-200 mcg/kg/minute; doses as low as 25 mcg/kg/minute may be adequate. Maintenance infusions may be continued for up to 48 hours). Acute coronary syndromes (when relative contraindications to betablockade exist; off-label use): IV: 0.5 mg/kg over 1 minute; follow with a 50 mcg/kg/minute infusion; if tolerated and response inadequate, may titrate upward in 50 mcg/kg/minute increments every 5-15 minutes to a maximum of 300 mcg/kg/minute (Mitchell, 2002); an additional bolus (0.5 mg/kg over 1 minute) may be administered prior to each increase in infusion rate. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 59 Electroconvulsive therapy (off-label use): 1 mg/kg administered IV, 1 minute prior to induction of anesthesia. Intubation (off-label use): 1-2 mg/kg IV given 1.5-3 minutes prior to intubation. Thyrotoxicosis or thyroid storm (off-label use): 50-100 mcg/kg/minute IV. Digoxin Brand Names: Digitek Digox Lanoxin Lanoxin Pediatric Pharmacologic Category Antiarrhythmic Agent, Miscellaneous Cardiac Glycoside Dosing: Preterm infant • Total digitalizing dose: – Oral: 20-30 mcg/kg – IV or IM: 15-25 mcg/kg • Daily maintenance dose: – Oral: 5-7.5 mcg/kg – IV or IM: 4-6 mcg/kg Full-term infant: • Total digitalizing dose: – Oral: 25-35 mcg/kg – IV or IM: 20-30 mcg/kg nursece4less.com nursece4less.com nursece4less.com nursece4less.com 60 • Daily maintenance dose: – Oral: 6-10 mcg/kg; and, IV or IM: 5-8 mcg/kg 1 month to 2 years: • Total digitalizing dose: – Oral: 35-60 mcg/kg – IV or IM: 30-50 mcg/kg • Daily maintenance dose: – Oral: 10-15 mcg/kg – IV or IM: 7.5-12 mcg/kg 2-5 years: • Total digitalizing dose: – Oral: 30-40 mcg/kg – IV or IM: 25-35 mcg/kg • Daily maintenance dose: – Oral: 7.5-10 mcg/kg – IV or IM: 6-9 mcg/kg 5-10 years: • Total digitalizing dose: – Oral: 20-35 mcg/kg – IV or IM: 15-30 mcg/kg • Daily maintenance dose: – Oral: 5-10 mcg/kg – IV or IM: 4-8 mcg/kg >10 years: • Total digitalizing dose: – Oral: 10-15 mcg/kg – IV or IM: 8-12 mcg/kg • Daily maintenance dose: – Oral: 2.5-5 mcg/kg – IV or IM: 2-3 mcg/kg Heart failure: A lower serum digoxin concentration may be adequate to treat heart failure (compared to cardiac arrhythmias); consider doses at the lower end of the recommended range for treatment of heart failure; a digitalizing dose (loading dose) may not be necessary when treating heart failure. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 61 Based on lean body weight and normal renal function for age. Decrease dose in patients with decreased renal function; digitalizing dose often not recommended in infants and children. Do not give full total digitalizing dose (TDD) at once. Give one-half of the total digitalizing dose (TDD) in the initial dose, then give one-quarter of the TDD in each of two subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity. Divided every 12 hours in infants and children <10 years of age. Give once daily to children >10 years of age and adults. IM not preferred due to severe injection site pain. If IM route is necessary, administer as deep injection followed by massage of injection site. Metoprolol ALERT: US Boxed Warning Ischemic heart disease Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction (MI) have occurred. When discontinuing chronically administered metoprolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1 to 2 weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstate metoprolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without their health care provider's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol therapy abruptly, even in patients treated only for hypertension. Brand Names: Lopressor Toprol XL nursece4less.com nursece4less.com nursece4less.com nursece4less.com 62 Pharmacologic Category Antianginal Agent Antihypertensive Beta-Blocker, Beta-1 Selective Dosing: Hypertension: Oral: Immediate release tablet (metoprolol tartrate): Children: 1 to 17 years: Initial: 1 to 2 mg/kg/day; maximum 6 mg/kg/day (≤200 mg daily); administer in 2 divided doses. Extended release tablet (metoprolol succinate): Children ≥6 years: Initial: 1 mg/kg once daily (maximum initial dose: 50 mg daily). Adjust dose based on patient response (maximum: 2 mg/kg/day or 200 mg daily). Use: Labeled Indications Immediate-release tablets (metoprolol tartrate): Treatment of angina pectoris, hypertension, or hemodynamically-stable acute myocardial infarction. Extended-release tablets (metoprolol succinate): Treatment of angina pectoris or hypertension; to reduce mortality/hospitalization in patients with heart failure (HF) (stable NYHA Class II or III) already receiving ACE inhibitors, diuretics, and/or digoxin. Injectable (metoprolol tartrate): Treatment of hemodynamically-stable acute myocardial infarction when used in conjunction with metoprolol oral maintenance therapy. Acute coronary syndromes (i.e., myocardial infarction, unstable angina): According to the ACCF/AHA 2013 guidelines for the management of STelevation myocardial infarction (STEMI) and the guidelines for the management of unstable angina/non-STEMI, oral beta-blockers should be initiated within the first 24 hours unless the patient has signs of heart failure, evidence of a low-output state, an increased risk for cardiogenic shock, or other contraindications. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 63 Intravenous use should be reserved for those patients who have refractory hypertension or ongoing ischemia. Heart failure: The ACCF/AHA 2013 heart failure guidelines recommend the use of 1 of 3 beta blockers (i.e., bisoprolol, carvedilol, or extended-release metoprolol succinate) for all patients with recent or remote history of MI or ACS and reduced ejection fraction (rEF) to reduce mortality, for all patients with rEF to prevent symptomatic HF (even if no history of MI), and for all patients with current or prior symptoms of HF with reduced ejection fraction (HFrEF), unless contraindicated, to reduce morbidity and mortality. Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD) recommends the use of a beta blocker as part of a regimen in patients with hypertension and chronic stable angina with a history of prior MI. A BP target of <140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (<130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 64 Acebutolol Brand Names: Sectral Pharmacologic Category Antiarrhythmic Agent, Class II Antihypertensive Beta-Blocker With Intrinsic Sympathomimetic Activity Beta-Blocker, Beta-1 Selective Dosing: Angina, ventricular arrhythmia: Oral: 400 mg/day in 2 divided doses; maintenance: 600 to 1200 mg/day in divided doses; maximum: 1200 mg/day Hypertension: Oral: Initial: 400 mg in 1 to 2 divided doses; optimal response usually seen at 400 to 800 mg daily (larger doses may be divided) although some patients may respond to as little as 200 mg daily; usual dose range: 200 to 400 mg daily; maximum dose: 1200 mg in 2 divided doses Chronic stable angina (off-label use): Oral: Usual dose: 400 to 1200 mg/day in 2 divided doses; low doses (i.e., 400 mg/day) may also be given as once daily. Use: Labeled Indications Treatment of hypertension; management of ventricular arrhythmias The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee, JNC 8; James, 2013) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients: • Patients ≥60 years of age with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg. • Patients <60 years of age with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with diabetes and SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 65 • Patients ≥18 years of age with chronic kidney disease (CKD) and SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. In patients with CKD, regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD), including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD), including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. Bisoprolol Brand Names: Zebeta Pharmacologic Category Antihypertensive Beta-Blocker, Beta-1 Selective Dosing: Adult Hypertension: Oral: Initial: 2.5 to 5 mg once daily; may be increased to 10 mg and then up to 20 mg once daily, if necessary; usual dose range: 5 to 10 mg once daily. Atrial fibrillation (rate control) (off-label use): Usual maintenance dose: 2.5 to 10 mg once daily. Heart failure (off-label use): Oral: Initial: 1.25 mg once daily; maximum dose: 10 mg once daily. (Note: Initiate only in stable patients or hospitalized patients after volume status has been optimized and IV diuretics, vasodilators, and inotropic agents have all been successfully discontinued). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 66 Caution should be used when initiating in patients who required inotropes during their hospital course. Increase dose gradually and monitor for congestive signs and symptoms of HF making every effort to achieve target dose shown to be effective Use: Labeled Indications Hypertension: Treatment of hypertension, alone or in combination with other agents Hypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients: • Patients ≥60 years of age, with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg. • Patients <60 years of age, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with diabetes, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with chronic kidney disease (CKD), with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 67 Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology and American Society of Hypertension 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD) recommends the use of a beta blocker as part of a regimen in patients with hypertension and chronic stable angina with a history of prior MI. A BP target of <140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (<130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents. Carvedilol Brand Names: Coreg Coreg CR Pharmacologic Category Antihypertensive Beta-Blocker With Alpha-Blocking Activity Dosing: Adult Reduce dosage if heart rate drops to <55 beats/minute. Hypertension: Oral: Immediate release: 6.25 mg twice daily; if tolerated, dose should be maintained for 1 to 2 weeks, then increased to 12.5 mg twice daily. If necessary, dosage may be increased to a maximum of 25 mg twice daily after 1 to 2 weeks. Usual dosage range: 6.25 to 25 mg twice daily. Extended release: Initial: 20 mg once daily, if tolerated, dose should be maintained for 1 to 2 weeks then increased to 40 mg once daily if necessary; if this dose is tolerated, maintain for 1 to 2 weeks then, if necessary, increase to 80 mg once daily; maximum dose: 80 mg once daily. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 68 Heart failure: Oral: (Note: Initiate only in stable patients or hospitalized patients after volume status has been optimized and IV diuretics, vasodilators, and inotropic agents have all been successfully discontinued. Caution should be used when initiating in patients who required inotropes during their hospital course. Increase dose gradually and monitor for congestive signs and symptoms of HF making every effort to achieve target dose shown to be effective). Immediate release: 3.125 mg twice daily for 2 weeks; if this dose is tolerated, may increase to 6.25 mg twice daily. Double the dose every 2 weeks to the highest dose tolerated by patient. (Prior to initiating therapy, other heart failure medications should be stabilized and fluid retention minimized). Maximum recommended dose: Mild-to-moderate heart failure <85 kg: 25 mg twice daily >85 kg: 50 mg twice daily Severe heart failure: 25 mg twice daily. Extended release: Initial: 10 mg once daily for 2 weeks; if the dose is tolerated, increase dose to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks. Maintain on lower dose if higher dose is not tolerated. (Note: The 2013 ACCF/AHA heart failure guidelines recommend a maximum dose of 80 mg once daily). Left ventricular dysfunction following MI: Oral: (Note: Should be initiated only after patient is hemodynamically stable and fluid retention has been minimized). Immediate release: Initial 3.125 to 6.25 mg twice daily; increase dosage incrementally (i.e., from 6.25 to 12.5 mg twice daily) at intervals of 3 to 10 days, based on tolerance, to a target dose of 25 mg twice daily. (Note: The 2013 ACCF/AHA heart failure guidelines recommend a maximum dose of 50 mg twice daily). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 69 Extended release: Initial: Extended release: Initial: 10 to 20 mg once daily; increase dosage incrementally at intervals of 3 to 10 days, based on tolerance, to a target dose of 80 mg once daily. Angina pectoris (off-label use): Oral: Immediate release: 25 to 50 mg twice daily. Atrial fibrillation (rate control) (off-label use): Usual maintenance dose: 3.125 to 25 mg twice daily. In patients with heart failure, the initial dose of 3.125 mg twice daily may be increased at 2-week intervals to a target dose of 25 mg twice daily (50 mg twice daily for patients weighing >85 kg). Conversion from immediate release to extended release (Coreg CR): Current dose immediate release tablets 3.125 mg twice daily: Convert to extended release capsules 10 mg once daily. Current dose immediate release tablets 6.25 mg twice daily: Convert to extended release capsules 20 mg once daily. Current dose immediate release tablets 12.5 mg twice daily: Convert to extended release capsules 40 mg once daily. Current dose immediate release tablets 25 mg twice daily: Convert to extended release capsules 80 mg once daily. Use: Labeled Indications Hypertension: Management of hypertension. The 2014 guideline for the management of high blood pressure in adults recommends initiation of pharmacologic treatment to lower blood pressure for the following patients: • Patients ≥60 years of age, with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg. • Patients <60 years of age, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with diabetes, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 70 • Patients ≥18 years of age with chronic kidney disease (CKD), with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. In patients with CKD, regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general non-black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. Heart failure: Mild to severe chronic heart failure of ischemic or cardiomyopathic origin (usually in addition to standard therapy, i.e., diuretics, ACE inhibitors). The ACCF/AHA 2013 heart failure guidelines recommend the use of 1 of the 3 beta blockers (i.e., bisoprolol, carvedilol, or extendedrelease metoprolol succinate) for all patients with recent or remote history of MI or ACS and reduced ejection fraction (rEF) to reduce mortality, for all patients with rEF to prevent symptomatic HF (even if no history of MI), and for all patients with current or prior symptoms of HF with reduced ejection fraction (HFrEF), unless contraindicated, to reduce morbidity and mortality. Left ventricular dysfunction following myocardial infarction (MI): Left ventricular dysfunction following MI (clinically stable with LVEF ≤40%). Propafenone ALERT: US Boxed Warning Mortality: In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non–life-threatening ventricular arrhythmias who had a myocardial infarction (MI) more than 6 days but less nursece4less.com nursece4less.com nursece4less.com nursece4less.com 71 than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide (class IC antiarrhythmics) compared with that seen in patients assigned to placebo (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (i.e., those without recent MI) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, generally avoid antiarrhythmic agents in patients with non– life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs. Brand Names: Rythmol Rythmol SR Pharmacologic Category Antiarrhythmic Agent, Class Ic Dosing: Patients who exhibit significant widening of QRS complex or second- or thirddegree AV block may need dose reduction. Atrial fibrillation (to prevent recurrence): Oral: Extended release capsule: Initial: 225 mg every 12 hours; dosage increase may be made at a minimum of 5-day intervals; may increase to 325 mg every 12 hours; if further increase is necessary, may increase to 425 mg every 12 hours Immediate release tablet: Initial: 150 mg every 8 hours; dosage increase may be made at minimum of 3- to 4-day intervals, may increase to 225 mg every 8 hours; if further increase is necessary, may increase to 300 mg every 8 hours. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 72 Paroxysmal supraventricular tachycardia (to prevent recurrence), ventricular arrhythmias: Oral: Immediate release tablet: Initial: 150 mg every 8 hours (US labeling) or 300 mg every 12 hours (Canadian labeling); dosage increase may be made at minimum of 3- to 4-day intervals, may increase to 225 mg every 8 hours; if further increase is necessary, may increase to 300 mg every 8 hours. Paroxysmal atrial fibrillation, pharmacologic cardioversion (off-label use): Oral: Immediate release tablet: Outpatient: "Pill-in-the-pocket" dose: 450 mg (weight <70 kg), 600 mg (weight ≥70 kg). May not repeat in ≤24 hours. (Note: An initial inpatient cardioversion trial should have been successful before sending patient home on this approach. Patient must be taking an AV nodal-blocking agent (e.g., beta-blocker, nondihydropyridine calcium channel blocker) prior to initiation of antiarrhythmic). Use: Labeled Indications Treatment of life-threatening ventricular arrhythmias; to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) or paroxysmal supraventricular tachycardia (PSVT) in patients with disabling symptoms without structural heart disease. Extended release capsule: Prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease Disopyramide ALERT: US Boxed Warning Mortality: In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had an MI more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 73 The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (i.e., those without recent MI) is uncertain. Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. Brand Names: Norpace Norpace CR Pharmacologic Category Antiarrhythmic Agent, Class Ia Dosing: Arrhythmias: Oral: Immediate release: <1 year: 10 to 30 mg/kg/24 hours in 4 divided doses 1 to 4 years: 10 to 20 mg/kg/24 hours in 4 divided doses 4 to 12 years: 10 to 15 mg/kg/24 hours in 4 divided doses 12 to 18 years: 6 to 15 mg/kg/24 hours in 4 divided doses Use: Labeled Indications Life-threatening ventricular arrhythmias (i.e., sustained ventricular tachycardia) Mexiletine ALERT: US Boxed Warning Mortality: In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non–life-threatening ventricular nursece4less.com nursece4less.com nursece4less.com nursece4less.com 74 arrhythmias who had an myocardial infarction (MI) more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (i.e., those without recent MI) is uncertain. Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. Acute liver injury: In postmarketing experience, abnormal liver function tests have been reported, some in the first few weeks of therapy with mexiletine. Most of these have been observed in the setting of congestive heart failure or ischemia and their relationship to mexiletine has not been established. Brand Names: Novo-Mexiletine Pharmacologic Category Antiarrhythmic Agent, Class Ib Dosing: Ventricular arrhythmias (life-threatening): Oral: Initial: 200 mg every 8 hours (may load with 400 mg if necessary); adjust dose in 50 or 100 mg increments no more frequently than every 2 to 3 days; usual dose: 200 to 300 mg every 8 hours; maximum dose: 1.2 g/day. (Note: Once controlled, patients may be transferred to an every 12-hour dosing schedule; do not exceed 450 mg every 12 hours with this regimen). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 75 Conversion: Switching from other oral antiarrhythmics (i.e., disopyramide, quinidine sulfate): Initiate 200 mg dose of mexiletine 6 to 12 hours after the last dose of the former agent. Switching from IV lidocaine: Initiate 200 mg dose of mexiletine when lidocaine infusion is stopped. Switching from oral procainamide: Initiate a 200 mg dose of mexiletine 3 to 6 hours after the last dose of procainamide. Premature ventricular complex (symptomatic) suppression (off-label use): Oral: 100 or 150 mg 3 times daily; if not controlled, may increase to 200 mg 3 times daily (Saikawa 1992; Tanabe 1991) or 100 or 200 mg 2 to 3 times daily; may progressively increase to a maximum dose of 500 mg 3 times daily. Use: Labeled Indications Ventricular arrhythmias: Management of life-threatening ventricular arrhythmias. (Note: The American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) states that mexiletine may be considered for those with long QT syndrome who present with torsades de pointes). Propranolol ALERT: US Boxed Warning Cardiac ischemia after abrupt discontinuation (Inderal LA, Inderal XL, Innopran XL): Following abrupt discontinuation of therapy with beta-blockers, exacerbations of angina pectoris and myocardial infarction (MI) have occurred. When discontinuing long-term administration of propranolol, particularly in patients with ischemic heart disease, gradually reduce the dose over a period of 1 to 2 weeks and monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, promptly resume therapy, at least temporarily, and take other measures appropriate for the management of unstable angina. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 76 Warn patients against interruption or discontinuation of therapy without health care provider's advice. Because coronary artery disease is common and may be unrecognized, avoid abrupt discontinuation of propranolol therapy, even in patients treated only for hypertension. Brand Names: Hemangeol Inderal LA Inderal XL InnoPran XL Pharmacologic Category Antianginal Agent Antiarrhythmic Agent, Class II Antihypertensive Beta-Blocker, Nonselective Dosing: Pediatric Proliferating infantile hemangioma (Hemangeol): Infants ≥2 kg: (Note: Initiate treatment at age 5 weeks to 5 months; doses should be administered at least 9 hours apart. Refer to product labeling for detailed weight-based dosing tabulation). Week 1: 0.15 mL/kg (~0.6 mg/kg) twice daily Week 2: 0.3 mL/kg (~1.1 mg/kg) twice daily Week 3 (maintenance): 0.4 mL/kg (~1.7 mg/kg) twice daily; maintain this dose for 6 months. Readjust dose periodically as the child's weight increases. Treatment may be reinitiated if hemangiomas recur. Hypertension (off-label use): Children and Adolescents: Oral: Immediaterelease formulations: Initial: 1 to 2 mg/kg/day divided in 2 to 3 doses/day; titrate dose to effect; maximum dose: 4 mg/kg/day up to 640 mg/day; sustained-release formulation may be dosed once daily. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 77 Thyrotoxicosis (off-label use): Adolescents: Oral: Immediate-release formulations: 10 to 40 mg/dose every 6 to 8 hours; may also consider administering extended or sustained release formulations. Use: Labeled Indications Management of hypertension; angina pectoris; pheochromocytoma; essential tremor; supraventricular arrhythmias (such as atrial fibrillation and flutter, AV nodal re-entrant tachycardias), ventricular tachycardias (catecholamineinduced arrhythmias, digoxin toxicity); prevention of myocardial infarction; migraine headache prophylaxis; symptomatic treatment of obstructive hypertrophic cardiomyopathy (formerly known as hypertrophic subaortic stenosis); treatment of proliferating infantile hemangioma requiring systemic therapy (Hemangeol only). Hypertension: The 2014 guideline for the management of high blood pressure in adults recommends initiation of pharmacologic treatment to lower blood pressure for the following patients: • Patients ≥60 years of age, with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg. • Patients <60 years of age, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with diabetes, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with chronic kidney disease (CKD), with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 78 In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. Beta-blockers are no longer recommended as first-line therapy in the general patient population. Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology, and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with CAD recommends the use of a beta blocker as part of a regimen in patients with hypertension and chronic stable angina with a history of prior MI. A BP target of <140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (<130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents (AHA/ACC/ASH) Ibutilide ALERT: US Boxed Warning Life-threatening arrhythmias: Ibutilide fumarate can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. In registration studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during or within a number of hours of using ibutilide fumarate. These arrhythmias can be reversed if treated promptly. It is essential that ibutilide be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia. Patients with atrial fibrillation of more than 2 to 3 days' duration must be adequately anticoagulated, generally at least 2 weeks. Appropriate treatment environment: Choice of patients: Patients with chronic atrial fibrillation have a strong tendency to revert after conversion to sinus rhythm and treatments to maintain sinus rhythm carry risks. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 79 Patients to be treated with ibutilide fumarate, therefore, should be carefully selected such that the expected benefits of maintaining sinus rhythm outweigh the immediate risks of ibutilide, and the risks of maintenance therapy, and are likely to offer an advantage compared with alternative management. Brand Names: Corvert Pharmacologic Category Antiarrhythmic Agent, Class III Dosing: Atrial fibrillation/flutter: IV: <60 kg: 0.01 mg/kg over 10 minutes ≥60 kg: 1 mg over 10 minutes (Note: Discontinue infusion if arrhythmia terminates, if sustained or nonsustained ventricular tachycardia occurs, or if marked prolongation of QT/QTc occurs. If the arrhythmia does not terminate within 10 minutes after the end of the initial infusion, a second infusion of equal strength may be infused over a 10-minute period). Dofetilide ALERT: US Boxed Warning Arrhythmias: To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. Brand Names: Tikosyn nursece4less.com nursece4less.com nursece4less.com nursece4less.com 80 Pharmacologic Category Antiarrhythmic Agent, Class III Dosing: (Note: CrCl and QTc (or QT interval if heart rate is <60 beats/minute) must be determined prior to first dose. If QTc >440 msec (>500 msec in patients with ventricular conduction abnormalities), dofetilide is contraindicated). Atrial fibrillation/atrial flutter: Initial: 500 mcg twice daily orally (maximum dose: 500 mcg twice daily). Initial dosage must be adjusted in patients with estimated CrCl <60 mL/minute (see dosage adjustment in renal impairment). Dofetilide may be initiated at lower doses than recommended based on health care provider discretion. Modification of dosage in response to initial dose: QTc interval should be measured 2 to 3 hours after the initial dose. If the QTc increases to more than 15% above baseline QTc or if the QTc is >500 msec (>550 msec in patients with ventricular conduction abnormalities), dofetilide dose should be reduced. If the starting dose was 500 mcg twice daily, then reduce to 250 mcg twice daily. If the starting dose was 250 mcg twice daily, then reduce to 125 mcg twice daily. If the starting dose was 125 mcg twice daily, then reduce to 125 mcg once daily. If at any time after the second dose is given the QTc is >500 msec (>550 msec in patients with ventricular conduction abnormalities), dofetilide should be discontinued. Maintenance therapy: No further down titration of dose based on QTc is recommended following modification of initial dose. Renal function and QTc should be re-evaluated every 3 months or as medically warranted. If QTc >500 msec (>550 msec in patients with ventricular conduction abnormalities), discontinue therapy. If renal function deteriorates, adjust dose as described in dosage adjustment in renal impairment. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 81 Use: Labeled Indications Atrial fibrillation/atrial flutter: Maintenance of normal sinus rhythm in patients with chronic atrial fibrillation/atrial flutter of longer than 1-week duration who have been converted to normal sinus rhythm; conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. Dronedarone ALERT: US Boxed Warning Increased risk of death, stroke, and heart failure: Dronedarone is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or New York Heart Association (NYHA) class IV heart failure. Dronedarone doubles the risk of death in these patients. Dronedarone is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AF, dronedarone doubles the risk of death, stroke, and hospitalization for heart failure. Brand Names: Multaq Pharmacologic Category Antiarrhythmic Agent, Class III Dosing: (Note: Prior to initiation of dronedarone, class I or III antiarrhythmics (i.e., amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) or drugs that are strong inhibitors of CYP3A (i.e., ketoconazole) must be stopped). Paroxysmal or persistent atrial fibrillation: Oral: 400 mg twice daily. Use: Labeled Indications Paroxysmal or persistent atrial fibrillation: To reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 82 Verapamil Brand Names: Calan Calan SR Covera-HS [DSC] Isoptin SR Verelan Verelan PM Pharmacologic Category Antianginal Agent Antiarrhythmic Agent, Class IV Antihypertensive Calcium Channel Blocker Calcium Channel Blocker, Nondihydropyridine Dosing: SVT: (Note: Verapamil is no longer included in the Pediatric Advanced Life Support (PALS) tachyarrhythmia algorithm). Children: 1-15 years: IV: 0.1 to 0.3 mg/kg/dose over 2 minutes; maximum: 5 mg/dose, may repeat dose in 30 minutes if inadequate response; maximum for second dose: 10 mg Use: Labeled Indications IV: Supraventricular tachyarrhythmia (PSVT, atrial fibrillation/flutter [rate control]) Oral: Treatment of hypertension; angina pectoris (vasospastic, chronic stable, unstable) (Calan, Covera-HS); supraventricular tachyarrhythmia (PSVT, atrial fibrillation/flutter [rate control]) Acute coronary syndrome (ACS): The ACCF/AHA guidelines for the management of unstable angina/non-ST-elevation myocardial infarction recommend verapamil to treat hypertension or ongoing ischemia if betablocker therapy is ineffective or contraindicated and in the absence of left ventricular dysfunction, pulmonary congestion, or AV block. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 83 Hypertension: The 2014 guideline for the management of high blood pressure in adults recommends initiation of pharmacologic treatment to lower blood pressure for the following patients: • Patients ≥60 years of age with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg. • Patients <60 years of age with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with diabetes with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. • Patients ≥18 years of age with chronic kidney disease (CKD) with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg. Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB. Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD) recommends that a non-dihydropyridine CCB (verapamil, diltiazem) may be used as a substitute for a beta blocker in patients who have an intolerance or contraindication to beta blockers with ongoing ischemia, hypertension and chronic stable angina, or if angina or hypertension continues to be uncontrolled while receiving standard therapies (i.e., beta blocker). However, a non-dihydropyridine CCB (i.e., verapamil, diltiazem) should be avoided in patients with LV dysfunction or heart failure (with reduced ejection fraction). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 84 A BP target of <140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (<130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents. Dipyridamole Brand Names: Persantine Pharmacologic Category Antiplatelet Agent Vasodilator Dosing: Adjunctive therapy for prophylaxis of thromboembolism with cardiac valve replacement: Oral: 75 to 100 mg 4 times/day Evaluation of coronary artery disease: IV: 0.56 mg/kg over 4 minutes; maximum dose: 70 mg. Following completion of dipyridamole infusion, inject radiotracer (i.e., thallium-201) in 3 to 5 minutes. (Note: To reverse complications and side effects of dipyridamole, aminophylline (50 to 250 mg IV push over 30 to 60 seconds given at least 1 minute after the radiotracer injection) should be available for urgent/emergent use). Obesity: Dosing for patients who are obese or morbidly obese is not established; in these patients, it is customary to use doses up to the weight of 125 kg. Use: Labeled Indications Oral: Used with warfarin to decrease thrombosis in patients after artificial heart valve replacement. IV: Diagnostic agent in CAD. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 85 Cardiac Pacemakers And Defibrillators Pacemakers sense electrical events and respond when necessary by delivering electrical stimuli to the heart. Permanent pacemaker leads are placed via thoracotomy or transvenously, but some temporary emergency pacemaker leads can be placed on the chest wall. Indications for Pacemaker Placement Indications are numerous but generally involve symptomatic bradycardia or high-grade atrioventricular (AV) block. Some tachyarrhythmias may be terminated by overdrive pacing with a brief period of pacing at a faster rate; the pacemaker is then slowed to the desired rate. Nevertheless, ventricular tachyarrhythmias are better treated with devices that can cardiovert and defibrillate as well as pace (implantable cardioverter defibrillators). Types of Pacemakers Types of pacemakers are designated by 3 to 5 letters, representing which cardiac chambers are paced, which chambers are sensed, how the pacemaker responds to a sensed event (inhibits or triggers pacing), whether it can increase heart rate during exercise (ratemodulating), and whether pacing is multisite (in both atria, both ventricles, or more than one pacing lead in a single chamber). For example, a VVIR pacemaker paces (V) and senses (V) events in the ventricle, inhibits pacing in response to sensed event (I), and can increase its rate during exercise (R). VVI and DDD pacemakers are the devices most commonly used. They offer equivalent survival benefits. Compared with VVI pacemakers, nursece4less.com nursece4less.com nursece4less.com nursece4less.com 86 physiologic pacemakers (AAI, DDD, VDD) appear to reduce risk of atrial fibrillation (AF) and heart failure and slightly improve quality of life.32,183 Advances in pacemaker design include lower-energy circuitry, new battery designs, and corticosteroid-eluting leads (which reduce pacing threshold), all of which increase pacemaker longevity. Mode switching refers to an automatic change in the mode of pacing in response to sensed events (i.e., from DDDR to VVIR during AF).83,84 Complications of Pacemaker Use Pacemakers may malfunction by oversensing or undersensing events, failing to pace or capture, or pacing at an abnormal rate. Tachycardias are an especially common complication. Ratemodulating pacemakers may increase stimuli in response to vibration, muscle activity, or voltage induced by magnetic fields during MRI. In pacemaker-mediated tachycardia, a normally functioning dualchamber pacemaker senses a ventricular premature or paced beat transmitted to the atrium through the AV node or a retrogradeconducting accessory pathway, which triggers ventricular stimulation in a rapid, repeating cycle.25 Additional complications associated with normally functioning devices include cross-talk inhibition, in which sensing of the atrial pacing impulse by the ventricular channel of a dual-chamber pacemaker leads to inhibition of ventricular pacing, and pacemaker syndrome, in which AV asynchrony induced by ventricular pacing causes fluctuating, vague cerebral (i.e., light-headedness), cervical (i.e., neck pulsations), or respiratory (i.e., dyspnea) symptoms. Pacemaker nursece4less.com nursece4less.com nursece4less.com nursece4less.com 87 syndrome is managed by restoring AV synchrony by atrial pacing (AAI), single-lead atrial sensing ventricular pacing (VDD), or dualchamber pacing (DDD), most commonly the latter. Environmental interference comes from electromagnetic sources such as surgical electrocautery and MRI, although MRI may be safe when the pacemaker generator and leads are not inside the magnet. Cellular telephones and electronic security devices are a potential source of interference; telephones should not be placed close to the device but are not a problem when used normally for talking. Walking through metal detectors does not cause pacemaker malfunction as long as patients do not linger. Defibrillators Direct-Current (DC) Cardioversion-Defibrillation A transthoracic DC shock of sufficient magnitude depolarizes the entire myocardium, rendering the entire heart momentarily refractory to repeat depolarization. Thereafter, the most rapid intrinsic pacemaker, usually the sinoatrial node, reassumes control of heart rhythm. Thus, DC cardioversion-defibrillation very effectively terminates tachyarrhythmias that result from reentry. However, it is less effective for terminating tachyarrhythmias that result from automaticity because the return rhythm is likely to be the automatic tachyarrhythmia. For tachyarrhythmias other than ventricular fibrillation (VF), the DC shock must be synchronized to the QRS complex (called DC cardioversion) because a shock that falls during the vulnerable period (near the peak of the T wave) can induce VF. In VF, synchronization of a shock to the QRS complex is neither nursece4less.com nursece4less.com nursece4less.com nursece4less.com 88 necessary nor possible. A DC shock applied without synchronization to a QRS complex is DC defibrillation. Procedure for DC cardioversion When DC cardioversion is elective, patients should fast for 6 to 8 h to avoid the possibility of aspiration. Because the procedure is frightening and painful, brief general anesthesia or IV analgesia and sedation (i.e., fentanyl 1 mcg/kg, then midazolam 1 to 2 mg q 2 min to a maximum of 5 mg) is necessary. Equipment and personnel to maintain the airways must be present. The electrodes (pads or paddles) used for cardioversion may be placed anteroposteriorly (along the left sternal border over the 3rd and 4th intercostal spaces and in the left infrascapular region) or anterolaterally (between the clavicle and the 2nd intercostal space along the right sternal border and over the 5th and 6th intercostal spaces at the apex of the heart). After synchronization to the QRS complex is confirmed on the monitor, a shock is given. The most appropriate energy level varies with the tachyarrhythmia being treated. Cardioversion efficacy increases with use of biphasic shocks, in which the current polarity is reversed part way through the shock waveform.85 DC cardioversion-defibrillation can also be applied directly to the heart during a thoracotomy or through use of an intracardiac electrode catheter; then, much lower energy levels are required. Complications of DC cardioversion Complications are usually minor and include atrial and ventricular premature beats and muscle soreness. Less commonly, but more nursece4less.com nursece4less.com nursece4less.com nursece4less.com 89 likely if patients have marginal left ventricular function or multiple shocks are used, cardioversion precipitates myocyte damage and electromechanical dissociation. Implantable Cardioverter-Defibrillators Implantable cardioverter-defibrillators cardiovert or defibrillate the heart in response to ventricular tachycardia (VT) or ventricular fibrillation (VF). Contemporary tiered-therapy ICDs also provide antibradycardia pacing and antitachycardia pacing (to terminate responsive atrial or ventricular tachycardias) and store intracardiac electrograms. The ICDs are implanted subcutaneously or subpectorally, with electrodes inserted transvenously into the right ventricle and sometimes also the right atrium. A biventricular ICD also has a left ventricular epicardial lead placed via the coronary sinus venous system or via thoracotomy. ICDs are the preferred treatment for patients who have had an episode of VF or hemodynamically significant VT not due to reversible or transient conditions (i.e., electrolyte disturbance, antiarrhythmic drug proarrhythmia, acute MI). ICDs may also be indicated for patients with VT or VF inducible during an electrophysiologic study and for patients with idiopathic or ischemic cardiomyopathy, a left ventricular ejection fraction of < 35%, and a high risk of VT or VF. Other indications are less clear.86 Because ICDs treat rather than prevent VT or VF, patients prone to these arrhythmias may require both an ICD and antiarrhythmic drugs nursece4less.com nursece4less.com nursece4less.com nursece4less.com 90 to reduce the number of episodes and need for uncomfortable shocks; this approach also prolongs the life of the ICD. Impulse generators for ICDs typically last about 5 years. ICDs may malfunction by delivering inappropriate pacing or shocks in response to sinus rhythm, SVTs, or nonphysiologically generated impulses (i.e., due to lead fracture). They also may malfunction by not delivering appropriate pacing or shocks when needed because of factors such as lead or impulse generator migration, undersensing, an increase in pacing threshold due to fibrosis at the site of prior shocks, and battery depletion. In patients who report that the ICD has discharged but that no associated symptoms of syncope, dyspnea, chest pain or persistent palpitations occurred, follow up with the ICD clinic and/or the electrophysiologist within the week is appropriate. The ICD can then be electronically interrogated to determine the reason for discharge. If such associated symptoms were present, or the patient received multiple shocks, emergency department referral is indicated to look for a treatable cause (i.e., coronary ischemia, electrolyte abnormality) or device malfunction.87 Cardiac Resynchronization Therapy In some patients, the normal, orderly, sequential relationship between contraction of the cardiac chambers is disrupted (becomes dyssynchronous). Dyssynchrony may be: 1) Atrioventricular, between atrial and ventricular contraction, 2) Interventricular, between left and right ventricular contraction, and 3) Intraventricular, between different segments of left ventricular contraction. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 91 Patients at risk for dyssynchrony include those with: ischemic or nonischemic dilated cardiomyopathy, prolonged QRS interval (≥ 130 msec), left ventricular end-diastolic dimension ≥ 55 mm, and left ventricular ejection fraction ≤ 35% in sinus rhythm. Cardiac resynchronization therapy (CRT) involves use of a pacing system to resynchronize cardiac contraction. Such systems usually include a right atrial lead, right ventricular lead, and left ventricular lead. Leads may be placed transvenously or surgically via thoracotomy. In heart failure patients with New York Heart Association (NYHA) class II, III, and IV symptoms, CRT can reduce hospitalization for heart failure and reduce all-cause mortality. However, there is little to no benefit in patients with permanent atrial fibrillation, right bundle branch block, nonspecific intraventricular conduction delay, or only mild prolongation of QRS duration (< 150 msec). Cardiac Ablation If a tachyarrhythmia depends on a specific pathway or ectopic site of automaticity, the site can be ablated by low-voltage, high-frequency (300 to 750 MHz) electrical energy, applied through an electrode catheter. This energy heats and necroses an area < 1 cm in diameter and up to 1 cm deep. Before energy can be applied, the target site or sites must be mapped during an electrophysiologic study. Success rate is > 90% for reentrant supraventricular tachycardias (via the atrioventricular [AV] node or an accessory pathway), focal atrial tachycardia and flutter, and focal idiopathic ventricular tachycardia (VT—right ventricular outflow tract, left septal, or bundle nursece4less.com nursece4less.com nursece4less.com nursece4less.com 92 branch reentrant VT). Because atrial fibrillation (AF) often originates or is maintained by an arrhythmogenic site in the pulmonary veins, this source can be electrically isolated by ablations at the pulmonary vein – left atrial junction or in the left atrium. Alternatively, in patients with refractory AF and rapid ventricular rates, the AV node may be ablated after permanent pacemaker implantation. RF ablation is sometimes successful in patients with VT refractory to drugs particularly when ischemic heart disease is present.58 The mortality rate of RF ablation is < 1/2000 and the procedure is considered to be safe. Complications include valvular damage, pulmonary vein stenosis or occlusion (if used to treat atrial fibrillation), stroke or other embolism, cardiac perforation, tamponade (1%), and unintended AV node ablation.40 Summary An arrhythmia is any abnormality in the rate, regularity, or site of origin or a disturbance in conduction that disrupts the normal sequence of activation in the atria or ventricles. Arrhythmias can be due to a variety of reasons, such as electrolyte abnormalities, structural abnormalities, metabolic derangements, genetic mutations, and drug toxicity. Arrhythmias have varying degrees of severity and significance based on site of origin, symptoms, frequency, and duration. Abnormal heart rates in children are often not a cause of concern, but it is absolutely vital that a healthcare professional be able to recognize when an arrhythmia has the potential to become serious or life threatening, and to identify appropriate treatment options. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 93 Arrhythmias may or may not present with secondary symptoms and it often requires some investigation to determine if a cause for the arrhythmia is present. Understanding the mechanics of arrhythmias as well as the treatment options will ensure that you are able to communicate with your patient and his or her parents to determine the right course of action. Please take time to help NurseCe4Less.com course planners evaluate the nursing knowledge needs met by completing the self-assessment of Knowledge Questions after reading the article, and providing feedback in the online course evaluation. Completing the study questions is optional and is NOT a course requirement. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 94 1. Any electrical activity not initiated by the SA node is considered a. b. c. d. a depolarization event. an atrioventricular (AV) impulse. an arrhythmia. a repolarization event. 2. Electrical stimulation of a myocardial cell results in a. b. c. d. a slow outward leak of sodium. depolarization. a slow outward leak of potassium. All of the above 3. True or False: Some arrhythmias are so common as to be considered as almost normal variants. a. True b. False 4. The conduction system in the ventricles is more elaborate than that in the atria because a. b. c. d. the muscle mass is larger. of the location of the bundle of His. the superior vena cava enters through the ventricles. of fiber stretch. 5. Normally, the _________________, located where the superior vena cava meets the right atrium, has the most rapid intrinsic rate (60 to 100 bpm). a. b. c. d. atria via atrioventricular (AV) node coronary sinus sinoatrial (SA) node nursece4less.com nursece4less.com nursece4less.com nursece4less.com 95 6. In general, arrhythmia mechanisms are described as abnormalities in a. b. c. d. electrical development. electrical conduction. a combination of electrical development and conduction. All of the above 7. _________________ ions cause the actual muscular contraction by coupling with the muscle fibers. a. b. c. d. Potassium Calcium Sodium None of the above 8. The atrial muscle and ventricular muscle are separated by insulation of the fibrous mitral and tricuspid valve rings, and normally the only connection between them is via a. b. c. d. the the the the superior vena cava. Bachmann bundle. His bundle. Purkinje fibers. 9. The ventricle is activated through the dense network of _____________ originating from the bundle branches. a. b. c. d. the Bachmann bundle Purkinje fibers the His bundle the superior vena cava 10. True or False: The mechanism of abnormal automaticity is NOT similar to the normal automaticity of sinus node cells. a. True b. False nursece4less.com nursece4less.com nursece4less.com nursece4less.com 96 11. Conduction block or conduction delay is a frequent cause of ____________________, especially if the conduction block is located in the cardiac conduction system. a. b. c. d. bradyarrhythmias tachyarrhythmias depolarization muscular contraction 12. Ion channels are passages for ions that facilitate a. b. c. d. muscular contraction. movement through the cell membrane. and AV reentry. and fiber stretch. 13. True or False: By far the most common tachycardia presenting in early infancy is orthodromic AV reentry. a. True b. False 14. Depolarization is initiated by a. b. c. d. the sodium channel closing a slow inward leak of sodium. an outward movement of potassium ions. a complex exchange of sodium, calcium, and potassium. 15. The final conducting components of the ventricles are the ____________, which emanate from the bundle branches to stimulate the ventricular cardiac muscle to contract. a. b. c. d. bundle of His catecholamines Purkinje fibers tricuspid valve rings 16. The QRS complex from an electrocardiogram measures a. b. c. d. both ventricular depolarization and repolarization. depolarization of the ventricles. repolarization. atrial activity. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 97 17. The conduction pathways through the atrium to the AVnode show preferential conduction due to a. b. c. d. their connection to the Bachmann bundle. their specialized conduction properties. phase 4 diastolic depolarization. their anatomical structure. 18. True or False: Conduction between the AV node and the bundle of His is measured by the P-R interval (the time between atrial activity and ventricular activity). a. True b. False 19. The anterior internodal pathway (through the atrium to the AV-node) connects to the anterior interatrial band, also known as a. b. c. d. the the the the anterior internodal pathway. Purkinje fibers. Bachmann bundle. His bundle. 20. The connection between atria and ventricles is facilitated through a. b. c. d. the the the the AV node. sinus node. interventricular septum. junction with the septum. 21. The normal average heart rate of children a. b. c. d. is higher than that of adults. varies from 60 bpm (at rest). varies up to 220 bpm during strenuous activities. All of the above nursece4less.com nursece4less.com nursece4less.com nursece4less.com 98 22. True or False: Many children with palpitations do not have an arrhythmia and a detailed first-hand history is essential before assessing the likelihood of an arrhythmia and the necessity of further investigation. a. True b. False 23. When diagnosing a child with an arrhythmia, diagnosis is based mainly on a. b. c. d. the child’s age and the age of onset of arrhythmia. the history (palpitations, heart failure, syncope, etc.). the ECG findings. All of the above 24. Infants generally have heart rates a. b. c. d. greater greater greater greater than than than than 60 60 80 80 bpm bpm bpm bpm and and and and less less less less than than than than 120 140 170 220 bpm. bpm. bpm. bpm. 25. Common arrhythmias in neonates with structurally normal hearts include a. b. c. d. sinus tachycardia. sinus bradycardia. atrioventricular reentry tachycardia (AVRT). complete AV block. 26. A head-up tilt test is sometimes used for investigation of ______________ with recurrent syncope or presyncope. a. b. c. d. infants children older than 6 years children between 3 and 6 years neonates nursece4less.com nursece4less.com nursece4less.com nursece4less.com 99 27. During the head-up tilt test, a. b. c. d. blood pressure is recorded continuously. the ECG is recorded continuously. The patient is passively tilted to an angle of 60–80. All of the above 28. True or False: The first scheme (Vaughan-Williams) is still the one that most physicians use when speaking of antiarrhythmic drugs. a. True b. False 29. In the Vaughan-Williams antiarrhythmic drugs classifications, _____________ are a class I drug. a. b. c. d. sodium channel blockers beta-blockers nondihydropyridine calcium channel blockers digoxin and adenosine 30. Class Ic antiarrhythmic drugs have slow kinetics so they express their electrophysiologic effects at _____ heart rates. a. b. c. d. fast slow intermediate all 31. __________________________ are not included in the Vaughan Williams classification. a. b. c. d. Sodium channel blockers Digoxin and adenosine Beta-blockers Nondihydropyridine calcium channel blockers nursece4less.com nursece4less.com nursece4less.com nursece4less.com 100 32. True or False: Dronedarone is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. a. True b. False 33. Class I drugs are subdivided based on the kinetics of the sodium channel effects: Class Ia drugs have ___________ kinetics. a. b. c. d. fast slow intermediate intermittent 34. In the Vaughan-Williams antiarrhythmic drugs classifications, _____________ are a class II drug. a. b. c. d. sodium channel blockers beta-blockers nondihydropyridine calcium channel blockers digoxin and adenosine 35. True or False: Proarrhythmia is a drug-related arrhythmia that is worse than the arrhythmia being treated, and it is an adverse effect of class I drugs. a. True b. False 36. Class Ib drugs have fast kinetics so they a. have major effects on atrial tissue. b. are very potent antiarrhythmics. c. express their electrophysiologic effects only at fast heart rates. d. All of the above nursece4less.com nursece4less.com nursece4less.com nursece4less.com 101 37. Class II drugs are contraindicated in a. b. c. d. glaucoma patients. older patients. asthma patients. patients with sinus tachycardia. 38. ______________ is intended for use only in patients with indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity. a. b. c. d. Nadolol Amiodarone Sotalol Diltiazem 39. When discontinuing nadolol administered long-term, particularly in patients with ischemic heart disease, a. b. c. d. gradually reduce dose over a period of 1 to 2 days. nadolol may not be reintroduced. the drug should be stopped abruptly. gradually reduce dose over a period of 1 to 2 weeks. 40. The use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes a. b. c. d. in non-white populations. in non-black populations. depending on diabetes status. regardless of race or diabetes status. 41. True or False: It may be prudent not to discontinue nadolol therapy abruptly in patients with possible coronary artery disease but it is prudent in patients being treated ONLY for hypertension. a. True b. False nursece4less.com nursece4less.com nursece4less.com nursece4less.com 102 42. Abnormal liver function tests have been reported, some in the first few weeks of therapy with a. b. c. d. an ACE inhibitor (ACEI). angiotensin receptor blocker (ARB). mexiletine. bisoprolol. 43. Permanent pacemaker leads are placed a. b. c. d. via thoracotomy or transvenously. on the chest wall. in the diaphragm. on the front of the breastbone. 44. Pacemakers may malfunction by a. b. c. d. oversensing events. undersensing events. failing to pace or capture, or pacing at an abnormal rate. All of the above 45. In patients with permanent atrial fibrillation (AF), __________ doubles the risk of death, stroke, and hospitalization for heart failure. a. b. c. d. dofetilide dronedarone bisoprolol digoxin 46. True or False: To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed in a facility for at least 3 days for calculations of creatinine clearance, continuous ECG monitoring, and cardiac resuscitation. a. True b. False nursece4less.com nursece4less.com nursece4less.com nursece4less.com 103 47. Severe exacerbation of angina and the occurrence of myocardial infarction (MI) and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with a. b. c. d. dofetilide beta-blockers. bisoprolol digoxin 48. Class III drugs are membrane stabilizing drugs, primarily a. b. c. d. fast-channel blockers. beta-blockers. calcium channel blockers. potassium channel blockers. 49. True or False: Because class Ia drugs have intermediate kinetics, their fast-channel tissue conduction slowing effects WILL be evident on an ECG obtained during normal rhythm at normal rates. a. True b. False 50. Class IV drugs are the nondihydropyridine a. b. c. d. fast-channel blockers. beta-blockers. calcium channel blockers. potassium channel blockers. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 104 CORRECT ANSWERS: 1. Any electrical activity not initiated by the SA node is considered c. an arrhythmia. 2. Electrical stimulation of a myocardial cell results in b. depolarization. 3. True or False: Some arrhythmias are so common as to be considered as almost normal variants. a. True 4. The conduction system in the ventricles is more elaborate than that in the atria because a. the muscle mass is larger. 5. Normally, the _________________, located where the superior vena cava meets the right atrium, has the most rapid intrinsic rate (60 to 100 bpm). d. sinoatrial (SA) node 6. In general, arrhythmia mechanisms are described as abnormalities in d. All of the above 7. _________________ ions cause the actual muscular contraction by coupling with the muscle fibers. b. Calcium 8. The atrial muscle and ventricular muscle are separated by insulation of the fibrous mitral and tricuspid valve rings, and normally the only connection between them is via c. the His bundle. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 105 9. The ventricle is activated through the dense network of _____________ originating from the bundle branches. b. Purkinje fibers 10. True or False: The mechanism of abnormal automaticity is NOT similar to the normal automaticity of sinus node cells. b. False 11. Conduction block or conduction delay is a frequent cause of ____________________, especially if the conduction block is located in the cardiac conduction system. a. bradyarrhythmias 12. Ion channels are passages for ions that facilitate b. movement through the cell membrane. 13. True or False: By far the most common tachycardia presenting in early infancy is orthodromic AV reentry. a. True 14. Depolarization is initiated by b. a slow inward leak of sodium. 15. The final conducting components of the ventricles are the ____________, which emanate from the bundle branches to stimulate the ventricular cardiac muscle to contract. c. Purkinje fibers 16. The QRS complex from an electrocardiogram measures b. depolarization of the ventricles. 17. The conduction pathways through the atrium to the AVnode show preferential conduction due to d. their anatomical structure. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 106 18. True or False: Conduction between the AV node and the bundle of His is measured by the P-R interval (the time between atrial activity and ventricular activity). a. True 19. The anterior internodal pathway (through the atrium to the AV-node) connects to the anterior interatrial band, also known as c. the Bachmann bundle. 20. The connection between atria and ventricles is facilitated through a. the AV node. 21. The normal average heart rate of children d. All of the above 22. True or False: Many children with palpitations do not have an arrhythmia and a detailed first-hand history is essential before assessing the likelihood of an arrhythmia and the necessity of further investigation. a. True 23. When diagnosing a child with an arrhythmia, diagnosis is based mainly on d. All of the above 24. Infants generally have heart rates c. greater than 80 bpm and less than 170 bpm. 25. Common arrhythmias in neonates with structurally normal hearts include c. atrioventricular reentry tachycardia (AVRT). nursece4less.com nursece4less.com nursece4less.com nursece4less.com 107 26. A head-up tilt test is sometimes used for investigation of ______________ with recurrent syncope or presyncope. b. children older than 6 years 27. During the head-up tilt test, d. All of the above 28. True or False: The first scheme (Vaughan-Williams) is still the one that most physicians use when speaking of antiarrhythmic drugs. a. True 29. In the Vaughan-Williams antiarrhythmic drugs classifications, _____________ are a class I drug. a. sodium channel blockers 30. Class Ic antiarrhythmic drugs have slow kinetics so they express their electrophysiologic effects at _____ heart rates. d. all 31. Vaughan Williams classification. b. Digoxin and adenosine 32. True or False: Dronedarone is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. a. True 33. Class I drugs are subdivided based on the kinetics of the sodium channel effects: Class Ia drugs have ___________ kinetics. c. intermediate nursece4less.com nursece4less.com nursece4less.com nursece4less.com 108 34. In the Vaughan-Williams antiarrhythmic drugs classifications, _____________ are a class II drug. b. beta-blockers 35. True or False: Proarrhythmia is a drug-related arrhythmia that is worse than the arrhythmia being treated, and it is an adverse effect of class I drugs. a. True 36. Class Ib drugs have fast kinetics so they c. express their electrophysiologic effects only at fast heart rates. 37. Class II drugs are contraindicated in c. asthma patients. 38. ______________ is intended for use only in patients with indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity. b. Amiodarone 39. When discontinuing nadolol administered long-term, particularly in patients with ischemic heart disease, d. gradually reduce dose over a period of 1 to 2 weeks. 40. The use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes d. regardless of race or diabetes status. 41. True or False: It may be prudent not to discontinue nadolol therapy abruptly in patients with possible coronary artery disease but it is prudent in patients being treated ONLY for hypertension. b. False nursece4less.com nursece4less.com nursece4less.com nursece4less.com 109 42. Abnormal liver function tests have been reported, some in the first few weeks of therapy with c. mexiletine. 43. Permanent pacemaker leads are placed a. via thoracotomy or transvenously. 44. Pacemakers may malfunction by d. All of the above 45. In patients with permanent atrial fibrillation (AF), __________ doubles the risk of death, stroke, and hospitalization for heart failure. b. dronedarone 46. True or False: To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed in a facility for at least 3 days for calculations of creatinine clearance, continuous ECG monitoring, and cardiac resuscitation. a. True 47. Severe exacerbation of angina and the occurrence of myocardial infarction (MI) and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with b. beta-blockers. 48. Class III drugs are membrane stabilizing drugs, primarily d. potassium channel blockers 49. True or False: Because class Ia drugs have intermediate kinetics, their fast-channel tissue conduction slowing effects WILL be evident on an ECG obtained during normal rhythm at normal rates. b. False nursece4less.com nursece4less.com nursece4less.com nursece4less.com 110 50. Class IV drugs are the nondihydropyridine c. calcium channel blockers References Section The reference section of in-text citations include published works intended as helpful material for further reading. Unpublished works and personal communications are not included in this section, although may appear within the study text. 1. Bijjani et al. Arrhythmia Detection. Pat Appl Publ. 2015; http://www.nhlbi.nih.gov/health/health-topics/topics/arr/ 2. Grace AA, Roden DM. Systems biology and cardiac arrhythmias. Lancet. 2012;380:1498–508. 3. Kalin A, Usher-Smith J, Jones VJ, Huang CLH, Sabir IN. Cardiac Arrhythmia: A Simple Conceptual Framework. Trends in Cardiovascular Medicine. 2010. p. 103–7. 4. Sali A, Vitetta L. Integrative medicine and arrhythmias. Australian Family Physician. 2007. p. 527–8. 5. Jaeggi E, Öhman A. Fetal and Neonatal Arrhythmias. Clinics in Perinatology. 2016. p. 99–112. 6. Cummings S, Priori SG. Genetics of cardiac arrhythmias. Minerva Medica. 2011. p. 209–22. 7. Lévy S, Olshansky B. Arrhythmia management for the primary care clinician. UpToDate. 2015. 8. Goodhart GW. Cardiac arrhythmia. Br Med J. 1995;2(2):1135. 9. Antzelevitch C, Burashnikov A. Overview of Basic Mechanisms of Cardiac Arrhythmia. Cardiac Electrophysiology Clinics. 2011. p. 23–45. 10. Benson DW. Genetic origins of pediatric heart disease. Pediatric Cardiology. 2010. p. 422–9. 11. Katz AM. Arrhythmias. Physiology of the Heart. 2010. p. 431–87. 12. Badhwar N, Kusumoto F, Goldschlager N. Arrhythmias in the coronary care unit. J Intensive Care Med. 2012;27(5):267–89. 13. Trappe H-J. [Tachycardias. What must the emergency physician know?]. Med Klin Intensivmed Notfmed. 2012;107(5):351–7. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 111 14. Ivanova D, Temelkov A. Management of perioperative arrhythmias. Anaesthesiol Intensive Care. 2010;40:14–20. 15. Duygu B, Poels EM, da Costa Martins P a. Genetics and epigenetics of arrhythmia and heart failure. Front Genet. 2013;4(October):219. 16. Camm AJ. Cardiac arrhythmias—trials and tribulations. The Lancet. 2012. p. 1448–51. 17. Baretti R, Debus B, Lin BS, Weng YG, Pasic M, Hübler M, et al. Arrhythmia post heart transplantation. Transplantationsmedizin Organ der Dtsch Transplantationsgesellschaft. 2011;23(3):198– 209. 18. Raghavendra BS, Bera D, Bopardikar AS, Narayanan R. Cardiac arrhythmia detection using dynamic time warping of ECG beats in e-healthcare systems. 2011 IEEE International Symposium on a World of Wireless, Mobile and Multimedia Networks, WoWMoM 2011 - Digital Proceedings. 2011. 19. Prosek R. Electrical cardioversion of sustained ventricular tachycardia in three Boxers. J Am Vet Med Assoc. 2010;236(5):554–7. 20. Gonzalez-Torrecilla E, Arenal A, Atienza F, Datino T, Atea LF, Calvo D, et al. EGC diagnosis of paroxysmal supraventricular tachycardias in patients without preexcitation. Annals of Noninvasive Electrocardiology. 2011. p. 85–95. 21. Kim C, Youn JE, Choi HE. The Effect of a Self Exercise Program in Cardiac Rehabilitation for Patients with Coronary Artery Disease. Annals of Rehabilitation Medicine. 2011. p. 381. 22. Hoyt W, Snyder CS. The asymptomatic Wolff-Parkinson-White syndrome. Prog Pediatr Cardiol. 2013;35(1):17–24. 23. Al-Ahmad A, Shenasa M, Shenasa H, Soleimanieh M. Incessant ventricular tachycardia and fibrillation: Electrical storms. Cardiac Electrophysiology Clinics. 2014. p. 613–21. 24. Colucci RA, Silver MJ, Shubrook J. Common types of supraventricular tachycardia: Diagnosis and management. Am Fam Physician. 2010;82(8):942–52. 25. Seiler J. [Treatment of bradycardias - who needs a pacemaker?]. Ther Umsch. 2014;71(2):105–10. 26. Brockmann E P, Wiechers C, Pantalitschka T, Diebold J, Vagedes J, Poets F C. Under-recognition of alarms in a neonatal intensive care unit. Arch Dis Child -- Fetal Neonatal Ed. 2013;98:F524–7. 27. Antzelevitch C, Burashnikov A. Mechanisms of cardiac arrhythmia. Electrical Diseases of the Heart: Volume 1: Basic Foundations and Primary Electrical Diseases. 2013. p. 93–128. 28. Grace AA, Roden DM. Systems biology and cardiac arrhythmias. The Lancet. 2012. p. 1498–508. 29. Badhwar N, Kusumoto F, Goldschlager N. Arrhythmias in the nursece4less.com nursece4less.com nursece4less.com nursece4less.com 112 coronary care unit. J Intensive Care Med. 2011;27:267–89. 30. Joglar J a, Page RL. Management of arrhythmia syndromes during pregnancy. Curr Opin Cardiol. 2014;29(1):36–44. 31. Leary MC, Veluz JS, Caplan LR. Neurologic complications of arrhythmia treatment. Handb Clin Neurol. 2014;119:129–50. 32. Conen D, Adam M, Roche F, Barthelemy JC, Felber Dietrich D, Imboden M, et al. Premature atrial contractions in the general population: Frequency and risk factors. Circulation. 2012;126(19):2302–8. 33. Adams JC, Srivathsan K, Shen WK. Advances in management of premature ventricular contractions. Journal of Interventional Cardiac Electrophysiology. 2012. p. 137–49. 34. Yamada T, McElderry HT, Doppalapudi H, Epstein AE, Plumb VJ, Kay GN. Catheter ablation of premature ventricular contractions arising from the mitral annulus after mitral valvoplasty. PACE Pacing Clin Electrophysiol. 2009;32(6):825–7. 35. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013;167(5):2300–5. 36. Monteforte N, Napolitano C, Priori SG. Genetics and arrhythmias: diagnostic and prognostic applications. Rev Esp Cardiol (Engl Ed). 2012;65:278–86. 37. Shen MJ, Choi E-K, Tan AY, Lin S-F, Fishbein MC, Chen LS, et al. Neural mechanisms of atrial arrhythmias. Nature reviews. Cardiology. 2012. 30-9 p. 38. Maeno Y, Hirose A, Kanbe T, Hori D. Fetal arrhythmia: Prenatal diagnosis and perinatal management. Journal of Obstetrics and Gynaecology Research. 2009. p. 623–9. 39. Kutlu Y, Kuntalp D. A multi-stage automatic arrhythmia recognition and classification system. Comput Biol Med. 2011;41(1):37–45. 40. Haqqani HM, Roberts-Thomson KC. Radiofrequency catheter ablation for ventricular tachycardia. Heart Lung Circ. 2012;21(67):402–12. 41. Pellegrini CN, Scheinman MM. Clinical management of ventricular tachycardia. Curr Probl Cardiol. 2010;35(9):453–504. 42. Link MS. Evaluation and Initial Treatment of Supraventricular Tachycardia. N Engl J Med. 2012;367(15):1438–48. 43. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. Journal of the American College of Cardiology. 2013. p. 793–801. 44. Femenía F, Baranchuk A, Morillo C a. Inappropriate sinus tachycardia: current therapeutic options. Cardiol Rev. 2012;20(1):8–14. 45. Houmsse M, Tyler J, Kalbfleisch S. Supraventricular tachycardia causing heart failure. Curr Opin Cardiol. 2011;26(3):261–9. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 113 46. Medi C, Kalman JM, Freedman SB. Supraventricular tachycardia. Med J Aust. 2009;190(5):255–60. 47. Medi C, Kalman JM, Freedman SB. Supraventricular tachycardia. Med J Aust. 2009;190(5):255–60. 48. Linton NWF, Dubrey SW. Narrow complex (supraventricular) tachycardias. Postgrad Med J. 2009;85(1008):546–51. 49. Tsao S, Deal BJ. Management of symptomatic Wolff-ParkinsonWhite syndrome in childhood. Prog Pediatr Cardiol. 2013;35(1):7–15. 50. Dowd FJ. Wolff parkinson white syndrome. xPharm: The Comprehensive Pharmacology Reference. 2011. p. 1–7. 51. http://pediatricepsociety.org 52. Obeyesekere M, Gula LJ, Skanes AC, Leong-Sit P, Klein GJ. Risk of sudden death in wolff-parkinson-white syndrome: How high is the risk? Circulation. 2012;125(5):659–60. 53. Suzuki T, Nakamura Y, Yoshida S, Yoshida Y, Shintaku H. Differentiating fasciculoventricular pathway from Wolff-ParkinsonWhite syndrome by electrocardiography. Hear Rhythm. 2014;11(4):686–90. 54. Núñez F, Ruiz-Granell R, Martínez-Costa C, Morell S, Brines J. Safety and efficacy of flecainide in the treatment of symptomatic children with wolff-parkinson-white syndrome. Pediatr Cardiol. 2010;31(8):1162–5. 55. Wackel P, Beerman L, Arora G. Wolff-Parkinson-White syndrome and adenosine response in pediatric patients. PACE - Pacing Clin Electrophysiol. 2013;36(4):491–6. 56. Cai Q, Shuraih M, Nagueh SF. The use of echocardiography in Wolff-Parkinson-White syndrome. Int J Cardiovasc Imaging. 2012;28(4):725–34. 57. Walker J, Calkins H, Nazarian S. Evaluation of Cardiac Arrhythmia Among Athletes. Am J Med. 2010;123(12):1075–81. 58. Tung R, Boyle NG, Shivkumar K. Catheter ablation of ventricular tachycardia. Circulation. 2010. 59. Malik AK, Ching CK, Liew R, Chong DTT, Teo WS. Successful ablation of sinus node reentrant tachycardia using remote magnetic navigation system. Europace. 2012. p. 455–6. 60. Mittnacht AJC, Dukkipati S, Mahajan A. Ventricular Tachycardia Ablation. Anesth Analg. 2015;120(4):737–48. 61. Roden DM. Personalized medicine to treat arrhythmias. Curr Opin Pharmacol. 2014;15:61–7. 62. Benito B, Josephson ME. Ventricular tachycardia in coronary artery disease. Rev Esp Cardiol (Engl Ed). 2012;65(10):939–55. 63. Hoffmayer KS, Gerstenfeld EP. Diagnosis and Management of Idiopathic Ventricular Tachycardia. Curr Probl Cardiol. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 114 2013;38(4):131–58. 64. Li Q, Rajagopalan C, Clifford GD. Ventricular fibrillation and tachycardia classification using a machine learning approach. IEEE Trans Biomed Eng. 2014;61(6):1607–13. 65. Motonaga KS, Ceresnak SR, Hsia HH. Unusual Outflow Tract Ventricular Tachycardia. Cardiac Electrophysiology Clinics. 2016. p. 79–88. 66. Knollmann BC, Roden DM. A genetic framework for improving arrhythmia therapy. Nature. 2008;451(7181):929–36. 67. Rahman M, Nasor M. An algorithm for detection of arrhythmia. 2011 1st Middle East Conference on Biomedical Engineering, MECBME 2011. 2011. p. 243–6. 68. Hall SL, Lorenc T. Secondary prevention of coronary artery disease. Am Fam Physician. 2010;81:289–96. 69. Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia. Journal of the American College of Cardiology. 2012. p. 1993–2004. 70. Gerstenfeld EP. Introduction to Ventricular Tachycardia. Cardiac Electrophysiology Clinics. 2012. p. 603. 71. Lau EW. Infraatrial supraventricular tachycardias: Mechanisms, diagnosis, and management. PACE - Pacing and Clinical Electrophysiology. 2008. p. 490–8. 72. Semelka M, Gera J, Usman S. Sick sinus syndrome: A review. American Family Physician. 2013. p. 691–6. 73. Ewy GA. Sick sinus syndrome: synopsis. J Am Coll Cardiol. 2014;64(6):539–40. 74. Rogińska N, Bieganowska K. Sick sinus syndrome: a family study. Cardiol Young. 2014;24(01):136–9. 75. Anderson JB, Benson DW. Genetics of sick sinus syndrome. Cardiac Electrophysiology Clinics. 2010. p. 499–507. 76. Sykes JA, Lubega J, Ezetendu C, Verma R, O’Connor B, Kalyanaraman M. Asymptomatic complete atrioventricular block in a 13-year-old girl. Pediatr Emerg Care. 2011;27(11):1081–3. 77. Barold SS, Herweg B. Second-degree atrioventricular block revisited. Herzschrittmachertherapie und Elektrophysiologie. 2012. p. 296–304. 78. Tobias JD, Chrysostomou C. Dexmedetomidine: Antiarrhythmic effects in the pediatric cardiac patient. Pediatric Cardiology. 2013. p. 779–85. 79. John RM, Tedrow UB, Koplan B a, Albert CM, Epstein LM, Sweeney MO, et al. Ventricular arrhythmias and sudden cardiac death. Lancet. 2012;380(9852):1520–9. 80. Lampert R. Evaluation and Management of Arrhythmia in the Athletic Patient. Prog Cardiovasc Dis. 2012;54(5):423–31. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 115 81. Conti CR. Re-thinking angina. Clinical Cardiology. 2007. 82. Zellerhoff S, Hinterseer M, Felix Krull B, Schulze-Bahr E, Fabritz L, Breithardt G, et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(5-6):483–6. 83. Ibrahim M, Hasan R. Pacemaker-mediated angina. Exp Clin Cardiol. 2013;18:35–7. 84. Venkatachalam KL. Common pitfalls in interpreting pacemaker electrocardiograms in the emergency department. J Electrocardiol. 2011;44:616–21. 85. Trappe H-J, Gummert J. Current pacemaker and defibrillator therapy. Dtsch Arztebl Int. 2011;108:372–9; quiz 380. 86. Hauser RG. The subcutaneous implantable cardioverterdefibrillator: Should patients want one? Journal of the American College of Cardiology. 2013. p. 20–2. 87. Buch E, Boyle NG, Belott PH. Pacemaker and defibrillator lead extraction. Circulation. 2011;123. The information presented in this course is intended solely for the use of healthcare professionals taking this course, for credit, from NurseCe4Less.com. The information is designed to assist healthcare professionals, including nurses, in addressing issues associated with healthcare. The information provided in this course is general in nature, and is not designed to address any specific situation. This publication in no way absolves facilities of their responsibility for the appropriate orientation of healthcare professionals. Hospitals or other organizations using this publication as a part of their own orientation processes should review the contents of this publication to ensure accuracy and compliance before using this publication. Hospitals and facilities that use this publication agree to defend and indemnify, and shall hold NurseCe4Less.com, including its parent(s), subsidiaries, affiliates, officers/directors, and employees from liability resulting from the use of this publication. The contents of this publication may not be reproduced without written permission from NurseCe4Less.com. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 116